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ABSTRACT OF THE DISSERTATION
Photoacoustic Imaging, Feature Extraction, and Machine Learning Implementation for Ovarian
and Colorectal Cancer Diagnosis
by
Eghbal Amidi
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2021
Professor Quing Zhu, Chair

Among all cancers related to women’s reproductive systems, ovarian cancer has the highest
mortality rate. Pelvic examination, transvaginal ultrasound (TVUS), and blood testing for cancer
antigen 125 (CA-125), are the conventional screening tools for ovarian cancer, but they offer very
low specificity. Other tools, such as magnetic resonance imaging (MRI), computed tomography
(CT), and positron emission tomography (PET), also have limitations in detecting small lesions.
In the USA, considering men and women separately, colorectal cancer is the third most common
cause of death related to cancer; for men and women combined, it is the second leading cause of
cancer deaths. It is estimated that in 2021, 52,980 deaths due to this cancer will be recorded. The
common screening tools for colorectal cancer diagnosis include colonoscopy, biopsy, endoscopic
ultrasound (EUS), optical imaging, pelvic MRI, CT, and PET, which all have specific limitations.
In this dissertation, we first discuss in-vivo ovarian cancer diagnosis using our coregistered
photoacoustic tomography and ultrasound (PAT/US) system. The application of this system is also
explored in colorectal cancer diagnosis ex-vivo. Finally, we discuss the capability of our
photoacoustic microscopy (PAM) system, complemented by machine learning algorithms, in
distinguishing cancerous rectums from normal ones.
xv

The dissertation starts with discussing our low-cost phantom construction procedure for preclinical experiments and quantitative PAT. This phantom has ultrasound and photoacoustic
properties similar to those of human tissue, making it a good candidate for photoacoustic imaging
experiments. In-vivo ovarian cancer diagnosis using our PAT/US system is then discussed. We
demonstrate extraction of spectral, image, and functional features from our PAT data. These
features are then used to distinguish malignant (n=12) from benign ovaries (n=27). An AUC of
0.93 is achieved using our developed SVM classifier. We then explain a sliding multi-pixel method
to mitigate the effect of noise on the estimation of functional features from PAT data. This method
is tested on 13 malignant and 36 benign ovaries. After that, we demonstrate our two-step
optimization method for unmixing the optical absorption (μa) of the tissue from the system
response (C) and Grüneisen parameter (Γ) in quantitative PAT (QPAT). Using this method, we
calculate the absorption coefficient and functional parameters of five blood tubes, with sO2 values
ranging from 24.9% to 97.6%.
We then demonstrate the capability of our PAT/US system in monitoring colorectal cancer
treatment as well as classifying 13 malignant and 17 normal colon samples. Using PAT features
to distinguish these two types of samples (malignant and normal colons), our classifier can achieve
an AUC of 0.93. After that, we demonstrate the capability of our coregistered photoacoustic
microscopy and ultrasound (PAM/US) system in distinguishing normal from malignant colorectal
tissue. It is shown that a convolutional neural network (CNN) significantly outperforms the
generalized regression model (GLM) in distinguishing these two types of lesions.

xvi

Chapter 1: Introduction
Ovarian cancer has the highest mortality rate among all cancers related to the reproductive system
of women. It is estimated that in 2021 in the USA, 21,410 new cases of ovarian cancer will be
diagnosed and 13,770 women will die of this cancer [1]. In the USA, colorectal cancer is the third
most common cause of deaths related to cancer in men and women considered separately, and the
second leading cause of cancer deaths when males and females are combined [2].
Photoacoustic imaging (PAI) is an imaging modality that advantageously combines the high
resolution of ultrasound (US) imaging with the high contrast of optical modalities [3-4].
Photoacoustic (PA) contrast is related to the tumor’s optical absorption, which is dependent on
tumor hypoxia and angiogenesis. PAI has been widely applied in diagnosing different cancers,
such as breast [5-7], thyroid [8-9], cervical [10], colorectal [11], and prostate cancers [12-13]), and
diseases like peripheral vascular diseases (PVDs) [14], joint inflammations [15-17], and skin
diseases [18-20]. By collecting PA data at four wavelengths, our lab has been able to use
photoacoustic tomography (PAT) to extract functional information from ovarian and colorectal
tissue. We have used blood oxygen saturation (sO2) and relative total hemoglobin (rHbT) to
develop classifiers that can successfully distinguish malignant from benign lesions.
This thesis begins by introducing ovarian and colorectal cancers. In the first chapter, we clarify the
importance of detecting these malignancies in their early stages, review statistics that are
concerning, and describe the limitations of current screening tools. We then introduce
photoacoustic imaging and discuss how this modality can help achieve early diagnosis of ovarian
and colorectal cancer.
1

In the second chapter of the dissertation, we introduce our low-cost phantom construction
procedure. Phantoms made using this procedure can be used in preclinical applications, e.g.,
ultrasound system calibration and quantitative photoacoustic tomography. Our gelatin-based
phantom includes evaporated milk to generate ultrasound attenuation, and it possesses ultrasound
and optical properties close to those of soft tissues. Two sets of phantoms are constructed to
explore the effects of the gelatin and evaporated milk concentrations on the phantom’s ultrasound
properties. The first set of phantoms contains different amounts of gelatin mixed with deionized
water (no evaporated milk in this set), while in the second set, the evaporated milk concentration
is varied (constant gelatin concentration). We measure the ultrasound attenuation of these
phantoms in low and high frequency ranges and show that when gelatin concentration is fixed at
5 %, the ultrasound attenuation varies from 0.4 to 0.6 dB/MHz/cm as the evaporated milk
concentration increases from 20% to 50%. After finding the concentration of gelatin and
evaporated milk that most closely approximates ultrasound attenuation of tissue, we add npropanol alcohol, glass microspheres, and Germall Plus preservative to our recipe. We then
measure the optical properties of the resulting phantom using a diffuse optical tomography (DOT)
system.
Next, we report the diagnostic results of in-vivo imaging of patients with ovarian lesions, using
our co-registered photoacoustic and ultrasound (PAT/US) system. A total of 39 ovaries from 24
patients are imaged in-vivo. We extract PAT functional features (sO2 and rHbT), PAT image
features, and PAT spectral features within a region of interest (ROI) in each ovary. To select the
significant features, a t-test is performed, and the independent predictors are determined by
evaluating the correlation between each pair of predictors. To classify the ovarian lesions, we
employ a generalized linear model (GLM) and a support vector machine (SVM). We use these
2

classifiers first to distinguish benign/normal lesions from ovaries with invasive epithelial tumors
and then to separate normal/benign lesions from all types of ovarian tumors. To assess the best
diagnostic performance of the classifiers when multiple wavelength data are available, we first
include PAT functional features. Next, we exclude the PAT functional features from the features
set to evaluate the best diagnostic performance if only a single wavelength is available. Our results
show that using functional features improves the classification performance, especially in
distinguishing normal/benign ovarian lesions from all types of tumors. In this case, the GLM
classifier yields an area under the ROC curve (AUC) of 0.92; the SVM classifier has an AUC of
0.93. When these features are excluded, the AUCs of the GLM and SVM are 0.89 and 0.92,
respectively.
Next, using our PAT data, we explain our multi-pixel procedure to reduce the effect of noise on
sO2 estimation in ovarian lesions. In PAT, a tunable laser typically illuminates the tissue at
multiple wavelengths, and the received photoacoustic waves are used to form functional images
of rHbT and sO2. Due to measurement errors, the estimation of these parameters can be
challenging, especially in clinical studies. We use a multi-pixel method to smooth the
measurements before calculating rHbT and sO2. We first perform phantom studies using blood
tubes of calibrated sO2 to evaluate the accuracy of our sO2 estimation. We then present diagnostic
results from PAT of 33 patients with 51 ovarian masses imaged by our PAT/US system. The
ovarian masses are divided into malignant and benign/normal groups. Using the PAT data from
all ovaries in these two groups, we construct functional maps of rHbT and sO2 and plot their
histograms. We also calculate the spectral features of the PAT data: their slope, intercept, and
midband fit. Support vector machine (SVM) models are trained on different combinations of the

3

significant features. An AUC of 0.93 (0.95%CI: 0.90 – 0.96) on the testing data set is achieved by
combining the mean sO2, the spectral intercept, and the score of the study radiologist.
We then discuss one of the challenges of quantitative photoacoustic (PA) imaging: unmixing the
optical absorption (μa) of the tissue from the system response (C) and Grüneisen parameter (Γ). In
this study, we calculate the absorption coefficient and functional parameters, i.e., the total
hemoglobin (HbT) and sO2 of five blood tubes with sO2 values ranging from 24.9% to 97.6% at
different depths in intralipid solution. Beer’s law is used to calculate the optical fluence in the
target area. Initial values for μa and C×Γ are found by fitting a line to the log of the PA beamform
envelope data. These initial values are iteratively updated using a conjugate gradient method, and
this process is repeated for all 11 wavelengths. The absorption coefficient spectrum follows the
molar extinction coefficient spectrum of deoxyhemoglobin for lower sO2 percentages, and it more
closely resembles the spectrum of oxyhemoglobin when the sO2 percentage increases. The
calculated absorption coefficients at 11 wavelengths are used to estimate the absolute value of the
HbT and sO2 of each blood sample at different depths. The mean errors of the estimated HbT
values for blood tubes at all depths, with respect to the real values, are less than 13%. Moreover,
the largest sO2 estimation error is 7.5%, for a blood sample with an sO2 of 24.9%. Our quantitative
PA method performs well for the data collected from blood samples, and we are investigating this
method further on our clinical data.
We then study the application of PAT in colorectal cancer diagnosis. This cancer is the second
most common malignancy diagnosed globally. Critical gaps exist in diagnostic and surveillance
imaging modalities for colorectal neoplasia. While prior studies have demonstrated the capability
of photoacoustic imaging techniques to differentiate normal from neoplastic tissue in the
gastrointestinal tract, the capability of evaluating tissue deeper than 1 cm with high speed and a
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large field of view remains limited. To investigate the ability of photoacoustic technology to image
deeper tissue, we conduct a pilot study using a real-time co-registered PAT and US system. A total
of 20 ex-vivo human colorectal tissue samples are imaged immediately after surgical resection.
Co-registered photoacoustic images of malignancies show significantly increased PAT signal
amplitude compared to normal regions of the same sample. Between untreated colorectal tumors
and normal tissue, there are statistically significant differences in the rHbT, in spectral features
(such as the mean spectral slope and the intercept extracted from PAT and US data), and in image
features (such as the first and second order statistics along with the standard deviation of the mean
radon transform of PAT images). In predicting histologically confirmed invasive carcinoma using
either a logistic regression model or a support vector machine, the combination of the rHbT and
PAT intercept parameters achieved the highest AUC value, 0.93, for the testing data set.
We then demonstrate the application of our novel photoacoustic microscopy/ultrasound
(PAM/US) endoscope in imaging post-treatment rectal cancer for surgical management of residual
tumor after radiation and chemotherapy. In this work, we compare the performance of the CNN
models to that of GLM models across 24 ex-vivo samples and 10 in-vivo patient examinations.
First order statistical features are extracted from histograms of PAM and US images to train,
validate, and test the GLM models, while PAM and US images are directly used to train, validate,
and test CNN models. The PAM-CNN model performs best, with an AUC of 0.96 (95% CI: 0.950.98), compared to the best PAM-GLM model using kurtosis, with an AUC of 0.82 (95% CI: 0.820.83). We also show that both CNN and GLMs derived from photoacoustic data outperform those
utilizing ultrasound alone. We conclude that pairing deep-learning neural networks with
photoacoustic images is the optimal analysis framework for determining the presence of residual
cancer in the treated human rectum.
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In the last chapter, we summarize the dissertation and outline future work in quantitative
photoacoustic tomography (QPAT) and the detection of nonvalid sO2 maps created from noisy
data in clinical applications.

1.1 Cancer
Throughout humans’ lifetimes, cells in different organs constantly die and are replaced with new
cells. Cancer starts when a group of cells start to grow in an uncontrollable manner. This abnormal
condition can appear as small or large tumors in an organ. The cancerous cells can also spread to
other organs and affect different parts of human’s body. American cancer society has estimated
that one in each three people are diagnosed with some type of cancer in their lifetime [21].
Therefore, this disease is a huge concern throughout the world, and in spite of all the advances in
medicine and related field, its treatment is still very difficult or, in many cases, impossible,
especially when it is diagnosed at later stages.

1.2 Ovarian cancer
1.2.1 Statistics
Among women, ovarian cancer is fifth most common cause of death due to cancer, and it is the
deadliest of all the gynecological cancers. According to the American Cancer Society, 21410
women will be diagnosed with ovarian cancer in the US in 2021, and 13770 deaths will be reported
[1]. If ovarian cancer is diagnosed at early stages, the 5-year survival rate can be higher than 90%.
Unfortunately, as ovaries are located deep in the abdominal cavity, the chance of noticing an
abnormality in this area is low when the tumor is at its early stages. Therefore, about 80% of
women are diagnosed with ovarian cancers at later stages (stage 3 or 4).
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1.2.2 Screening tools
A recent update from the U.S. Preventive Services Task Force has concluded that major trials of
promising ovarian cancer screening tools have null findings to date among healthy average-risk
women, and there are considerable harms associated with screening, which have included major
surgical complications in women found to have no cancer [22]. Women with a screening
abnormality will generally undergo prophylactic bilateral salpingo-oophorectomy. Prophylactic
salpingo-oophorectomy results in morbidity and mortality of premature menopause, including
accelerated bone loss and cardiovascular death. Current screening tools for ovarian cancer are
pelvic examinations, transvaginal ultrasound (US), and assessment of cancer antigen 125 (CA125)
serum marker levels with all provide high false-positive rate. Conventional MRI and diffusionweighted MRI can be also employed for ovarian cancer diagnosis, but they are expensive and are
useful just as follow up modalities in the investigation of sonographically indeterminate adnexal
masses. Moreover, computed tomography (CT) is non-specific for small lesions. Furthermore,
FDG-PET can measure the residual or recurrent disease and also help select the surgical treatment.
However, this modality has a limited value in lesion localization in the early stages of ovarian
cancer because of the difficulty in distinguishing between the signal from early-stage cancers and
the background uptake signals from the normal tissue. Thus, there is an urgent need to develop
better and more sensitive tools to effectively evaluate ovary.

1.3 Colorectal cancer
1.3.1 Statistics
In the USA, colorectal cancer is the third most common cause of deaths related to cancer in men
and women, and the second leading cause of cancer deaths in combined men and women group
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[2]. It's estimated that in 2021, 52980 deaths due to this cancer will be recorded. This cancer can
be in either of these 3 stages: localize, regional, and distal. The localize stage is the first stage of
colorectal cancer development, while the distal stage is its last stage. The survival rates of colon
cancer at these three stages are 91%, 72%, and 14%, respectively [2]. These numbers are 89%,
72%, and 16% for rectal cancer. Obviously, it is crucial for these cancers to be diagnosed as early
as possible.

1.3.2 Screening tools
Common screening tools for colorectal cancer diagnosis include: White light endoscopy which
only detects macroscopic morphology and provides no functional assessment of the imaged tissue.
EUS is another modality which is highly user-dependent and unable to resolve small islands of the
tumor. MRI has limited between-slice resolution and is often unable to differentiate early tumors
from benign neoplasia, committing patients to potentially more invasive treatment regimens than
needed. Monitoring of tumors after chemotherapy and radiation with MRI is often confounded by
fibrotic reaction and edema, which can appear similar to residual tumor. CT has poorer resolution
of the bowel wall layers in comparison to MRI, subsequently limiting its ability to describe
circumferential resection margin status or serosal invasion in locally advanced cases. Additionally,
CT also cannot distinguish induration or peritumoral fibrosis from frank malignant disease with a
high degree of specificity, further limiting its application in local tumor staging. Finally, PET is
plagued by poor resolution

1.4 Photoacoustic Imaging
Photoacoustic imaging is based on the generation of ultrasound waves using short pulse lasers.
When a tissue is shined by short pulsed lasers, it absorbs the optical energy of the laser, leading to
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its thermal expansion. This process generates ultrasound wave. The ultrasound waves that are
generated using the light energy are called photoacoustic (PA) waves. These waves are propagated
in the tissue and are detected by ultrasound detectors (transducers). If PA waves are detected by
multiple transducer elements, which is the case in photoacoustic tomography (PAT), an image
reconstruction technique can be used to form images from the detected PA waves. Unlike pure
optical modalities, the detected signals are actually ultrasound waves which are scattered in tissue
much less than optical waves. Moreover, unlike ultrasound modalities which contrast between
different areas is dependent on difference in structural/mechanical properties of those areas, in
photoacoustic modalities, the difference in optical properties is responsible for contrast between
different areas.

Therefore, photoacoustic imaging modalities offer the advantages of both

ultrasound imaging (high resolution) and optical imaging (high contrast) modalities.
Photoacoustic imaging modalities are divided into two main categories: photoacoustic tomography
(PAT), and photoacoustic microscopy (PAM). In PAT, usually an array of low frequency
ultrasound detectors is employed to collect PA data. As multiple detectors collect data at the same
time, data acquisition is fast in PAT. Moreover, as a wide laser beam is used to shine the tissue as
well as array transducers can easily be programmed to steer at various angles (by applying different
delays to transducer elements), a large field of view can be imaged using PAT. Finally, PAT can
image up to 5 to 7 cm (depending on the properties of tissue) at the cost of lower resolution than
PAM because it uses a low frequency transducer to detect PA signals.
PAM on the other hand, uses highly focused laser beams or ultrasound detectors to image tissue.
Optical-resolution PAM (OR-PAM) and acoustic-resolution PAM (AR-PAM) are two categories
of PAM. In OR PAM, the light beam is focused much tighter than acoustic beams while acoustic
beams are much more tightly focused than optical beams in AR-PAM. This modality is employed
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in this dissertation for colorectal cancer diagnosis as it provides better spatial resolution than ORPAM beyond the diffusion limit. Generally, PAM offers a better image resolution than PAT, but
it can only image a very limited depth in the tissue.
PAT uniquely provides functional imaging at high resolution using hemoglobin as an endogenous
contrast agent. The sO2 of the blood vessels in the lesion area can be calculated using PAT data.
PAT is a non-expensive, high resolution, high contrast imaging modality, which is able to identify
malignant or residual tumors, otherwise, undetectable by current clinical imaging.

References
1. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
2. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survivalrates.html
3. L. V. Wang, & S. Hu, “Photoacoustic tomography: in vivo imaging from organelles to
organs,” Science, 335(6075), 1458-1462, (2012).
4. L. V. Wang, & J. Yao, “A practical guide to photoacoustic tomography in the life
sciences,” Nature methods, 13(8), 627, (2016).
5. A. A. Oraevsky et al., “Clinical optoacoustic imaging combined with ultrasound for
coregistered functional and anatomical mapping of breast tumors,” Photoacoustics, 12, 3045, (2018).
6. L. Lin et al., “Single-breath-hold photoacoustic computed tomography of the
breast,” Nature communications, 9(1), 1-9, (2018).
7. L. Lin et al. "High-speed three-dimensional photoacoustic computed tomography for
preclinical research and clinical translation," Nature communications 12.1: 1-10 (2021).
10

8. W. Roll et al., “Multispectral Optoacoustic Tomography of Benign and Malignant Thyroid
Disorders: A Pilot Study,” Journal of Nuclear Medicine, 60(10), 1461-1466, (2019).
9. M. Yang et al., “Photoacoustic/ultrasound dual imaging of human thyroid cancers: an
initial clinical study,” Biomedical optics express, 8(7), 3449-3457, (2017).
10. K. Peng et al., “Detection of cervical cancer based on photoacoustic imaging—the in-vitro
results,” Biomedical optics express, 6(1), 135-143, (2015).
11. G. Yang et al., “Co-registered photoacoustic and ultrasound imaging of human colorectal
cancer,” Journal of biomedical optics, 24(12), 121913, (2019).
12. C. Liu et al., “In vivo transrectal imaging of canine prostate with a sensitive and compact
handheld transrectal array photoacoustic probe for early diagnosis of prostate cancer,”
Biomedical optics express, 10(4), 1707-1717, (2019).
13. V. S. Dogra et al., “Multispectral photoacoustic imaging of prostate cancer: preliminary
ex-vivo results,” Journal of clinical imaging science, 3, (2013).
14. Y. Wang et al., “A portable three-dimensional photoacoustic tomography system for
imaging of chronic foot ulcers,” Quantitative imaging in medicine and surgery, 9(5), 799,
(2019).
15. J. Jo et al., “A functional study of human inflammatory arthritis using photoacoustic
imaging,” Scientific reports, 7(1), 1-9, (2017).
16. P. J. van den Berg et al., “Feasibility of photoacoustic/ultrasound imaging of synovitis in
finger joints using a point-of-care system,” Photoacoustics, 8, 8-14, (2017).
17. J. Jo et al., “Photoacoustic tomography for human musculoskeletal imaging and
inflammatory arthritis detection,” Photoacoustics, 12, 82-89, (2018).

11

18. J. Aguirre et al., “Precision assessment of label-free psoriasis biomarkers with ultrabroadband optoacoustic mesoscopy,” Nature Biomedical Engineering, 1(5), 1-8, (2017).
19. J. Kim et al., “Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for
better selection of the excision margin,” British Journal of Dermatology, 179(3), 780-782,
(2018).
20. A. B. E. Attia et al., “Noninvasive real-time characterization of non-melanoma skin cancers
with handheld optoacoustic probes,” Photoacoustics, 7, 20-26 (2017).
21. https://www.cancer.org/
22. J. T. Henderson et al., “Screening for ovarian cancer: updated evidence report and
systematic review for the US preventive services task force,” JAMA. 13;319(6):595-606.
doi: 10.1001/jama.2017.21421. Review, (2018).

12

Chapter 2: Low-cost phantoms for
photoacoustic imaging
2.1 Introduction
Photoacoustic (PA) imaging has recently been widely used in clinical studies for cancer diagnosis
[1-6]. This modality is based on the generation of ultrasound waves using a short pulsed laser. This
means that the generated photoacoustic signals depend on both optical and ultrasound properties
of the medium. Thus, it is important to make a phantom which resembles both optical and
ultrasound properties of soft tissues. Such a phantom not only could be useful in photoacoustic
imaging for calibration purposes to cancel the system effect on the received PA signals [7, 8], but
also can be helpful in other optical modalities, such as optical coherence tomography [9-11] and
spectroscopy [12].
Tissue-mimicking ultrasound phantoms can be either in liquid or gelatin/agar-based form. Liquid
phantoms are not the subject of this study and are reviewed elsewhere [13]. Homogeneous gelatin/
agar based phantoms have been widely used, especially in the context of quantitative ultrasound
to cancel the ultrasound system effects. One of the earliest work on gelatin-based ultrasound
phantom construction was by Madsen et al. [14]. They made ultrasound phantoms with different
properties by changing the concentration of graphite powder and 1-propanol alcohol in their
phantom mixture. They were able to construct ultrasound phantoms with a speed of sound between
1520 and 1650 m/s and an ultrasound attenuation which ranged from 0.2 to 1.5 dB/cm/MHz. As
the graphite powder highly scattered ultrasound waves, this material was replaced with evaporated
milk in another study [15]. Agar-based phantoms made using this method mimicked ultrasound
properties of soft tissue. However, the optical properties of the phantoms were not measured in
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that study. A procedure to make gelatin-based phantoms which mimic both ultrasound and optical
properties of soft tissue is reported in [16]. In that study, Intralipid is used to enhance both optical
scattering and ultrasound attenuation. Moreover, to induce optical absorption, any one of India Ink
or Direct Red 81 or Evans Blue are added to the mixture.
Besides the ultrasonic and optical properties of phantoms, their durability is another important
factor to consider when making phantoms. For this reason, phantom recipes usually include adding
a preservative, such as Formaldehyde, Thimerosal, and Germall plus to the phantom mixture.
Furthermore, gelatin/agar based phantoms usually have to be kept in the fridge to protect them
from being spoiled.
In this study, we have made phantoms with different concentrations of gelatin and evaporated
milk. Then the ultrasound properties of these phantoms have been measured to see which phantom
provides the best ultrasound properties. Then n-propanol alcohol, glass spheres, and Germall plus
are added to the recipe and the optical properties of the resulted phantom are found using a diffuse
optical system (DOT) developed in our lab [17,18] to make sure that the phantom has optical
properties close to soft tissues.

2.2 Methods and Materials
2.2.1 Phantom construction procedure
First, to get some idea about the effect of evaporated milk and gelatin concentration on the
ultrasound properties of our phantom, we made two sets of phantoms. In the first set, different
phantoms were made by adding different amounts of gelatin to deionized water. No evaporated
milk was added to these phantoms. In the second set, we kept the concentration of gelatin at 5%
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and then added different amounts of evaporated milk. After realizing how the ultrasound properties
are affected by different concentrations of evaporated milk and gelatin, we added n-propanol, glass
spheres and Germall plus to our phantom recipe.
In this study, a procedure similar to that described in [15] was followed to make a gelatin-based
phantom with ultrasound and optical properties close to those of soft tissues. In table 2.1, the
materials used to make the phantom and the amount of each material can be found. To increase
the ultrasound attenuation, evaporated milk was employed in the phantom instead of the graphite
powder which was conventionally a component of ultrasound phantoms. The reason for this is that
besides high ultrasound scattering, graphite powder has a very high optical absorption, whereas
employing the evaporated milk results in a yellowish phantom with optical absorption and
scattering coefficients close to those of soft tissues. To control the speed of sound in the phantom,
n-propanol alcohol was added to the mixture. The higher amount of this material leads to a higher
speed of sound of the phantom. Moreover, 70 gr (100 beads/cm3) of 3000E glass microsphere
beads with a mean diameter of around 35 µm (Potters Industries Inc., Valley Forge, PA) were used
to enhance ultrasound scattering in the phantom. Finally, to protect the phantom from bacterial
invasion, Germall plus is added to the mixture.
The following is a summary of the step by step procedure of the phantom construction:
- The ultra-purified deionized water is mixed with n-propanol alcohol. The mixture is placed on
top of a magnetic stirrer and gelatin (G2500, Sigma-Aldrich Corp., St. Louis, MO) is gradually
added to the mixture. The magnetic stirrer heats up the mixture besides mixing its components.
This process of simultaneous heating and mixing is continued until a transparent mixture is
generated. Then the mixture is allowed to be cooled down.
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- The preservative is added to the evaporated milk and the mixture is heated up to the temperature
of 60 oC.
- The two mixtures generated in step 1 and 2 are then combined when they both reach a temperature
of 55oC. After that, the microspheres, which have been heated up to the same temperature, are
added to the mixture.
- The mixture is then poured into a flask for degassing to ensure that the phantom will not contain
any air bubbles. After that, a small portion of the mixture is poured into a cup for ultrasound
properties measurements, and the rest of it is transferred from the flask to a larger container to
measure the optical properties. Both the cup and container are kept in the fridge for 24 hours to
allow its solidification.
Table 2.1: The materials employed to make the phantom and the amount of each of them.
Material

Amount

Ultra-purified DI water

1L

Evaporated milk (unfiltered)

1L

Gelatin

100 gr

n-propanol alcohol

50 mL

microspheres

70 gr

Germall plus

25 gr

2.2.2 Ultrasound properties
The set up for ultrasound attenuation measurements is shown in Figure 2.1. The ultrasound signals
generated by the ultrasound (US) transmitter are received by a second transducer, once without
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phantom between the two transducers and a second time, in the presence of the phantom. The
phantom ultrasound attenuation is then calculated as

s ( f ) =

  V ( f , z )  −102  w ( f ) 
20
log10  r
10

z2
  Vs ( f , z ) 

z

Eq. (2.1)

where αs(f) is the phantom length, αw(f) is the ultrasound attenuation of water as a function of
frequency, and <Vr(f,z)> and <Vs(f,z)> are the Fourier transforms of the recorded ultrasound
signals before and after placing the phantom between the transducer and planar reflector,
respectively.

Figure 2.1: The setup used to measure the ultrasound attenuation coefficient

The speed of sound of our phantom was measured by a pulse-echo method. To calculate the speed
of sound, the phantom was placed inside the water tank filled with deionized water. A single
element transducer (with a 5.4MHz center frequency) generated an ultrasound pulse from the
transducer towards the phantom located at the focal distance of the transducer (8cm). This pulse
hits both surfaces of the phantom and reflects back towards the transducer. The speed of sound (c)
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in the phantom is a function of the temporal distance between the two reflections from proximal
and distal surfaces of the phantom (∆t) and the phantom length (z) and is given by

c=

Eq. (2.2)

2z
.
t

2.2.3 Optical properties
The reduced scattering and absorption coefficients of our phantom was measured using a diffuse
optical tomography (DOT) system developed in our lab [18]. This system consists of 9 sources
and 14 detectors. The optical sources transmit diffused lights sequentially, and every time the light
is detected by all detectors. For each source-detector pair, the amplitude and phase of the detected
signals are computed using a Hilbert transform. The log of amplitude and phase measurements at
different wavelengths can be plotted with respect to the source-detector distance (Figure 2.3) and
the optical scattering and absorption can then be calculated from these plots. A detailed description
about how to find the absorption and scattering coefficient using the amplitude and phase plots is
found in [19].

2.3 Results
2.3.1 Ultrasound and optical properties
Figure 2.2 shows the calculated ultrasound attenuations of the two sets of phantoms using (1) and
their linear fit within the -6dB bandwidth of the transducer. The top plots show the ultrasound
attenuation increases from 0.07 to 1.26 dB/cm/MHz when the gelatin concentration increases form
4% to 15%. The lower plots illustrate the effect of evaporated milk on the ultrasound attenuation.
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These phantoms have a fixed concentration of gelatin (5%). As can be seen, increasing the
evaporated milk concentration from 20 to 50 % results in increase of 0.2 dB/cm/MHz in the
ultrasound attenuation.

Figure 2.2: Top: The effect of gelatin concentration on ultrasound attenuation (no evaporated
milk in the mixture). Bottom: The effect of evaporated milk concentration on ultrasound
attenuation when the gelatin concentration is fixed at 5%. The plots on the left show the
ultrasound attenuation as a function of frequency, and those on the right are their associated
fitted lines.

Using the DOT system, we acquired the log of amplitude (left column) and the phase (right
column) measurements of the phantom introduced in Table 1 at 4 different wavelengths of 740,
780, 808, and 830 nm (Figure 2.3). These measurements were then used to calculate the absorption
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and reduced scattering coefficients of the phantom at these wavelengths. The results have been
summarized in Table 2.2. As can be seen, our phantom has optical properties very similar to those
of soft tissue.
Table 2.2: Absorption and reduced scattering coefficient of our phantom at 740, 780, 808, and
830 nm wavelengths
740 nm

780 nm

808 nm

830 nm

Absorption coefficient (cm-1)

0.029

0.034

0.027

0.032

Reduced scattering coefficient (cm-1)

10.41

9.21

9.21

8.74

740 nm

780 nm

20

808 nm

830 nm

Figure 2.3: The log of amplitude (left column) and the phase (right column) measurements of our
phantom at 740, 780, 808, and 830 nm wavelengths as a function of source-detector distance.

2.4 Discussion and Summary
In this study, a phantom was made which has acoustic and optical properties similar to soft tissues.
At first, we made phantoms with different concentration of gelatin and evaporated milk, and the
effect of each material on the ultrasound attenuation was investigated. The ultrasound attenuation
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was measured using two transducers, one of which was used to transmit the ultrasound waves and
the other one to receive the ultrasound signals. To calculate the optical properties of our phantom,
we used a DOT system developed in our lab. The results show that our phantom has ultrasound
and optical properties close to soft tissues. However, our study has two main limitations. First,
although evaporated milk is low cost, different brands of it with different fat concentrations will
affect acoustic and optical properties. Second, using DOT to calculate the optical properties is
suitable for measuring lower background optical absorption and scattering properties. Inverse
adding doubling sphere method is investigated to measure a range of optical properties of the
phantoms.
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Chapter 3: In-vivo ovarian cancer diagnosis
using coregistered photoacoustic tomography
and ultrasound system
3.1 Introduction
Among women, ovarian cancer is fifth most common cause of death due to cancer, and it is the deadliest
of all the gynecological cancers [1]. In 2019, an estimated 22,530 women were diagnosed in the United
States, and about 13,980 of these women died from this disease [2]. Due to the lack of early screening and
diagnostic techniques, many women are diagnosed with ovarian cancer when it is already at stages III or
IV, where the mortality rates are high (70 to 75%) [3,4]. Pelvic examination [5,6], transvaginal ultrasound
[7,8], and blood testing for CA-125 [8-9] are the conventional screening tests, but they all lack enough
specificity for early ovarian cancer diagnosis [9]. Moreover, imaging modalities such as computed
tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) have
been used for surgical guidance. However, all of these modalities have limitations: for example, they are
non-specific for small lesions (CT), costly (MRI), or need specific tracers and have difficulty in separating
tumors from background (MRI, PET) [10-12]. Clearly, improved diagnostic methods and more effective
detection tools are needed to diagnose ovarian cancer.
Recently, photoacoustic tomography (PAT) has been explored in medical diagnosis because it provides
functional information of biological tissue at ultrasound resolution. This modality is based on the
photoacoustic effect [13-15]. A pulsed laser light absorbed by tissue causes a local temperature increase
which creates thermoelastic expansion and generates photoacoustic waves. The propagated waves are then
detected by an ultrasound (US) transducer and used to reconstruct optical absorption distribution. If
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photoacoustic imaging is performed at two or more optical wavelengths, information about functional
parameters of a tissue, such as its rHbT and sO2, can be obtained.
Previously, our group performed a study on classification of excised ovarian samples [16]. In that study, an
average area under Receiver Operating Characteristic (ROC) curve (AUC) of 0.92 ± 0. 05 for 50 testing
samples was achieved using PAT spectral and beam envelope features along with several PAT image
features. In a subsequent study, US spectral features were added to the PAT features to evaluate the
classification performance on another set of excised ovaries [17]. It was demonstrated that the generalized
linear model (GLM) and support vector machine (SVM) classifiers could respectively achieve sensitivities
of 70.4 and 87.7%, and specificities of 95.6 and 97.9%, for the testing data. Moreover, two patients with
malignant and benign ovaries were imaged in-vivo in that study, but this number of patients was too low to
evaluate the performances of the classifiers. In our most recent study, we reported the imaging results of
co-registered US and PAT in a pilot group of 26 ovaries from16 patients. We demonstrated in this study
that the difference in rHbT was statistically significant between invasive epithelial ovarian cancers and
benign/normal ovarian masses (p=0.01), and the sO2 was statistically significant between invasive
epithelial ovarian cancers/other neoplasms and benign/normal ovarian masses (p=0.03) [18]. However, no
classification results and ROC analysis were reported in this first pilot group of patients.
In this study, we extracted the PAT functional, spectral, and image features from 24 patients of 39 ovaries
(mean age, 54 years; range, 34-76) and performed ROC analysis using the GLM and SVM classifiers. The
first 16 patients reported in [18] were included in this study for feature extraction and ROC analysis. We
categorized the ovarian lesions into three groups of benign/normal ovaries (n=27), invasive epithelial
cancers (n=9), and other types of neoplasms (n=3) (see Table 3.1). First, we developed GLM and SVM
classifiers to distinguish benign/normal ovaries from epithelial cancers only. Subsequently, we
differentiated benign/normal ovaries from all types of cancers (epithelial and other neoplasms) using new
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GLM and SVM classifiers. To evaluate the performances of the classifiers when the data from just one
wavelength is available, we repeated the same procedure to design GLM and SVM classifiers without
inclusion of PAT functional features in the features set. The performance of each classifier was evaluated
by computing its ROC curve for both training and testing data sets and calculating the area under these
curves. To the best of our knowledge, the reported patient diagnostic results using the GLM and SVM
classifiers with ROC analysis based on PAT features are the first of its kind and may improve current
practice on ovarian tissue diagnosis once the results are validated with a large patient pool.

3.2 Methods and Materials
3.2.1 Co-registered PAT/US System
The co-registered PAT/US system was described in detail in [18]. Briefly, this system consists of
a Ti-sapphire laser which can be tuned from 690 nm to 900 nm, a light delivery system that
includes four optical fibers coupled with a transvaginal transducer (6 MHz, 80% bandwidth), and
a commercial ultrasound system (EC-12R, Alpinion Medical Systems, Republic of Korea). The
system was programmed to image patients at four wavelengths (730, 780, 800, and 830 nm), and
at each wavelength, several (3-10) PAT and US frames were collected.

3.2.2 PAT functional features
The 𝑟𝐻𝑏𝑇 (𝑟, 𝜃) at each pixel in the region of interest (ROI) was calculated as the summation of
the relative oxyhemoglobin concentration 𝑟𝐻𝑏𝑂 (𝑟, 𝜃) and relative deoxyhemoglobin
concentration 𝑟𝐻𝑏 (𝑟, 𝜃) at that pixel. The relative oxy and deoxy hemoglobin concentrations can
be approximated as [19]
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rHbO(r , ) = C (r , ) HbO(r ,  ),

Eq. (3.1)

rHb(r , ) = C (r , ) Hb(r , ),

Eq. (3.2)

where C (r, ) = C0 (r, ) (r, ),

 is the tissue’s Grüneisen parameter, C0 (r ,  ) is the

system acoustic operator, and  (r ,  ) is the local fluence, which can be approximated as
wavelength independent at the narrow wavelength window we used. As can be seen in (1) and (2),
calculating the absolute values of oxy, deoxy, and total hemoglobin requires knowledge of the
local fluence in the tissue, which is difficult to estimate in clinical studies. For this reason, the
relative values of these parameters have been computed in this study. To calculate the mean rHbT
in the ROI, the maximum of this parameter in this region was found, and the average of the rHbT
values higher than half of this maximum value was then computed.
The blood sO2 at each pixel was calculated by dividing the oxyhemoglobin by the sum of the oxy
and deoxyhemoglobin:
sO 2(r ,  ) =

HbO(r ,  )
100%.
HbO(r ,  ) + Hb(r ,  )

Eq. (3.3)

Note that in sO2 calculation, the unknown C (r ,  ) is cancelled out in the numerator and
denominator of the division. We calculated the mean sO2 in the ROI by taking an average of sO2
values over pixels with a sO2 value higher than a noise threshold. Based on our system noise level,
this threshold was defined as 5% of the maximum SO2 in the ROI.

3.2.3 PAT spectral feature extraction
Photoacoustic spectral features have been shown to be valuable tools in clinical applications, such
as characterization of bone microstructure [20], quantification of normal and fatty livers [21],
28

cancer diagnosis [22-23], and monitoring cancer treatment response [24]. In earlier studies we
evaluated the feasibility of these features for distinguishing malignant from benign ex-vivo ovaries
[16-17]. Here, we extract these features from the data collected from in-vivo studies of patients.
To calculate the spectral features, co-registered ultrasound images were used to select an ROI
corresponding to the examined ovary. The angular beam segments in the ROI with a maximum
value greater than the noise level of our US system (60 mV for both PAT and US) were then
selected for spectral analysis. Each of these beams was gated using a Hamming window before its
spectrum was computed within a -10dB frequency range (0.5 to 4 MHz for PAT, and 3.5 to 7 MHz
for US) using a fast Fourier transform (FFT).
The transducer response was calibrated using several sets of calibration data. To generate each set
of data, we recorded the photoacoustic signals from a black string with a diameter of 250 µm at a
particular depth. Then the distance from the transducer to the string was varied from 0.5 cm to 7
cm in steps of 0.25 cm, and for each transducer-string distance a set of photoacoustic signals was
recorded and averaged. After that, the power spectra of these data were found using an FFT
algorithm. Finally, the power spectra of all PAT beam lines in the ROI of the examined ovary were
divided by this calibration spectrum, depending on the depth of the ROI center.
After calibration, a line was fitted to each of the calibrated PAT spectra, and the mean spectral
slope (SS), midband fit (MBF), and 0.5 MHz spectral intercept (0.5 MHz SI (PAT)) were obtained
from all fitted lines within the ROI. Although the 0 MHz intercept has been widely used as a
feature in the literature, we chose the 0.5 MHz spectral intercept instead because our transducer’s
lower band is at ~ 0.5 MHz.
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Figure 3.1 shows the mean spectra of PAT signals in the ROI (dashed rectangular area), along with
their fitted lines, for a benign mucinous cystadenoma (left) and an ovary of a high-grade serous
carcinoma (right). The SS, 0.5 MHz SI (PAT), and MBF of the mean PAT spectrum are also shown
in each image. Note that the spectral features were obtained at four different wavelengths (730,
780, 800, and 830 nm), but each feature was highly correlated for different wavelengths. Thus, the
spectral features at one wavelength (730 nm) were used for our classifiers.

Figure 3.1: Top row: co-registered rHbT and US images of a benign mucinous cystadenoma (a)
and a high-grade serous carcinoma (b). The vascular distribution of the benign lesion is more
scattered, but more localized and intense for the malignant ovary. Bottom row: the calibrated
PAT power spectra and their fitted lines in the regions associated with the angular dashed lines in
each image. Note the different Y-axis depth ranges.
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3.2.4 PAT image features
In addition to functional and spectral features, we observed that the textures of PAT images for
benign and malignant ovarian tissue look different in the patient data. This observation led us to
quantify this difference by calculating more imaging features from the PAT images. The first step
was to choose an ROI. To find the ROI in each frame, we first selected a larger rectangular region
associated with the ovarian tissue. Then the Radon transforms of the image at angles of 0 and 90
degrees in the ovary area were calculated. A Gaussian curve was fitted to each of them after they
were normalized to their peak values. The means of the Gaussian curves determined the center of
a 2 cm by 2 cm square where the image analysis was performed (Figure 3.2).
Second order statistics of the normalized PAT images were computed within the ROI. These
features provide information about the relation between pixel connections. To calculate the textural
features of the PAT images, a gray-level co-occurrence matrix was created [27]. This matrix had
dimensions of N*N, where N is the number of gray levels in the PAT image. In this study, we used
N=16. The value c(i,j) of the (i, j) element of the GLCM represents the number of times that gray
levels i and j are adjacent to each other in the PAT image. In the present study, we considered two
gray levels g1 and g2 as adjacent if g2 was located at the immediate right of g1. After forming the
GLCM matrix, the following four textural features were computed for each PAT image:
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Figure 3.2: ROI selection for image analysis. A larger rectangular region associated with the
ovarian tissue is first selected (a). After that, the Radon transforms of the image at angles of 0
and 90 degrees in the selected area are calculated (b). These Radon transforms are then
normalized, and a Gaussian curve is fitted to each of them. The means of the Gaussian curves
determine the center of a square with a side of 2 cm where the image analysis is performed.

Contrast =

N −1

N

Eq. (3.4)

N

Eq. (3.5)

2

|i − j| = 0

Correlation =

N

 | i − j |  c(i, j),
i =1 j =1

N

 (i −  )( j −  )c(i, j )
i

i =1 j =1

j

,

 i j
N

N

Energy =  c(i, j )2 ,

and

Eq. (3.6)

i =1 j =1

N

c(i, j ) 2
,
j =1 1+ | i − j |
N

Homogeneity = 
i =1

Eq. (3.7)

where N is the dimension of this matrix, and µ and σ are the mean and standard deviation for row i or
column j of the GLCM [26].
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Besides the second order statistics of the normalized PAT images, we calculated other features related to
the non-normalized PAT envelope data. Two features of this type include the standard deviation and fitting
error of the Gaussian function that is fitted to the mean Radon transform of the non-normalized PAT images
(std Rad). To calculate the mean Radon transform, we computed the Radon transform of the nonnormalized PAT images in the ROI for angles from 0 to 90 degrees, with a step size of one degree, and
took the average of them. Another feature that we extracted from the non-normalized images was the area
of the PAT image in the ROI. This parameter was defined as the percentage of the pixels in the ROI with a
value higher than the noise level. Other PAT image features, including malignant and benign spatial filters
and Rayleigh fit parameters, were also calculated, but no significant differences in these features were
observed between benign and malignant masses. A detailed explanation of how to calculate these features
can be found in [16].

3.2.5 Classification
We imaged 24 patients (39 ovaries) using our hybrid PAT/US system (see Table 3.1). Among
these, 17 patients (26 ovaries) had benign/normal ovaries, 4 patients (8 ovaries) had invasive
epithelial cancers, 1 patient had one normal ovary and one epithelial cancer, and the rest (2 patients,
3 ovaries) had other types of neoplasm. In this study, each ovary was considered as an independent
sample.
Table 3.1: Lesion Characteristics (24 patients, 39 ovaries; average age 54 years, range 34-76
years)
Invasive epithelial
ovarian cancer

high grade serous carcinoma (n=5), endometrioid carcinoma (n=4)
(average size 10 cm, range 2.8 - 20 cm)

Other neoplasm

serous borderline (n=2) tumor, sertoli-Leydig cell tumor (n=1) (average
size 11.1 cm, range 4.5-19.2 cm)

Benign ovaries

fibrothecoma (n=1, size 14 cm), mature teratoma (n=1, size 6 cm),
serous or mucinous cystadenoma or cystic endometriosis (n=11, average
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10.1 cm, range 1.8-37 cm), complex or simple cysts (n=10, average 4.5
cm, range 2.5-7.6 cm)
Normal ovaries

no histopathological abnormalities (n=4, average 2.4 cm, range 2.1 -2.8
cm)

Two types of linear classifiers were investigated in this study, i.e., GLM and SVM. GLM has proven to be
an excellent classifier for binary classification problems. To train this classifier, the true response (0 or 1) is
plotted as a function of the input parameters for each sample in the training data set. Then a logistic function
is fitted to the data points. Therefore, the output of this classifier is a value between 0 and 1 which represents
the probability of an observation belonging to an output category. To test this classifier, a threshold value
is defined to put each testing sample in one of the two classes (0 or 1). If the probability is less than this
threshold, the new sample is classified as label 0 and otherwise, as label 1. The ROC curve can be derived
by changing the threshold value and the AUC value can be computed to evaluate the performance of the
classifier.
In a binary SVM classification problem, the training data sets are plotted on an n-dimensional space, where
n indicates the number of input features. Then the support vectors, i.e., the points which are located nearest
to the margin of each of the two classes are found. These vectors are employed to find the hyperplane which
best separates the two classes. If the data sets are not linearly separable, a kernel function can be defined to
map the data to a higher dimension space. An SVM classifier which is developed using this method is
called a non-linear SVM with a kernel function. In this study, we used a linear SVM which has proved to
perform better than the non-linear SVM classifiers.
We first developed models to differentiate benign/normal masses from epithelial cancers. This was
performed by constructing GLM and SVM classifiers. We were also interested to find out how
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distinguishable the benign/normal group was from the epithelial and other neoplasm. Therefore, another
set of GLM and SVM classifiers were developed to achieve this goal.
To train each classifier, we used a cross-validation method with 200 iterations. In each iteration, two-third
of the data were randomly selected for training the classifier, and the rest were used for testing. For both
training and testing data sets, the ROC curves were calculated at each iteration. The mean ROCs were then
determined by taking an average over all individual ROCs, and the AUCs were then employed to evaluate
the performances of classifiers.
As previously discussed, the PAT functional features in our study were calculated by extracting PAT data
at four different wavelengths. However, we were also interested to see the performances of the classifiers
in the case when the PAT signals are acquired at one wavelength. This performance is very important to
evaluate the co-registered PAT and US technique if a laser system only has one wavelength available. For
this evaluation, the PAT functional features were excluded from the feature set and new classifiers were
constructed using other PAT features. These features were divided into three groups based on the
correlation value between each two features (Table 3.3). The highly correlated features were in one group.
Based on this criterion, the first group includes the PAT spectral feature only, i.e., 0.5 MHZ SI (PAT). The
second group includes area, contrast and correlation. Finally, the third group consists of the remaining
image feature, i.e., std Rad, which has low correlation values with all the other image features. To develop
the classifiers, we first used just 0.5 MHz SI (PAT). Then one feature in the second group whose
combination with 0.5 MHz SI (PAT) resulted in the highest testing AUC was added to the feature set.
Finally, std Rad was also included in the features set, and its effects on the performance of our classifiers
were investigated by evaluating the training and testing AUCs.
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3.3 Results
3.3.1 PAT spectral features
In Figure 3.1, the co-registered rHbT and US images of a benign (a) and an epithelial cancer (b)
are shown. The PAT spectral analysis for each of these ovaries was performed in the ROI
(specified by the dashed angular area). The plots of the average PAT spectra after calibration for
these ovaries along with their fitted lines are shown in the bottom row of the figure. As can be seen
in this figure, the value of the 0.5 MHz SI (PAT) of the ovary with an epithelial tumor is higher
than that for a benign/normal ovary. This is the only spectral feature which is significantly different
between benign/normal ovaries and the ovaries with epithelial cancers (P<0.05).

3.3.2 PAT image features
Co-registered PAT and US images of a set of benign fibrothecoma and high-grade serous
carcinoma are shown in Figure 3.3. The rectangular dashed area in each image indicates the region
where the PAT image analysis is performed. The center of this area was found using the Radon
transforms of the PAT signals as explained in the previous section. The images on the lower panel
are a zoom-in view of the PAT image in the selected rectangular area. As can be seen, the benign
ovary seems to have higher local variations in pixel values of the PAT image in comparison with
the malignant ovary which leads to a larger contrast and lower correlation value for the benign
ovary. The pixel values in the malignant ovary, on the other hand, seem to be more correlated than
those in the benign ovary, so a higher value of correlation is expected in the images of malignant
ovaries.
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3.3.3 Classification by inclusion of functional features in the features set
Classification of benign/normal ovaries and epithelial tumors
To determine the difference between the three groups of ovarian masses in terms of the extracted
features, a student t-tests was performed on each feature for each pair of the three groups. Then
the features with a p-value of less than 0.05 between benign/normal and epithelial cancer groups
were selected as the significant features. The box plots of these features are shown in Figure 3.4.
The p-value between each pair of groups can also be seen on each plot. As can be seen, except for
sO2, there is a higher similarity between “others” and “benign/normal” than “others” and
“epithelial cancer”. This suggests that “others” group may not be separable from “benign/normal”
group if no sO2 is used.

Figure 3.3: Co-registered PAT and US images and magnification of the PAT images in the areas
indicated by the dashed rectangle for a benign fibrothecoma (a) and an ovary with epithelial
cancer (b). The values of the textural features for each image are also shown.
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Figure 3.4: Box plots of the significant features for the three groups of ovaries. For each feature,
the p-value between each pair of the three groups is shown in the plots.

First, we have constructed GLM and SVM models to distinguish the benign/normal group from
the epithelial cancer group. Note that a key step in any classification algorithm is model
construction using a proper set of representative predictors. A proper set includes a combination
of features which are highly correlated with the class labels (0 or 1), but poorly correlated with
each other. To evaluate the correlation between each feature and the class label and between each
two features, Spearman’s rho value was calculated. After that, we ranked the features based on the
value of Spearman’s correlation between each feature and the labels. This ranking for the seven
significant features, along with the ranking based on the p-values, is shown in Table 3.2. As can
be seen, rHbT is at the top of the ranking, based on Spearman’s correlation as well as p values.
Also note that, although 0.5 MHz SI (PAT) has a lower p-value than std Rad, it is ranked lower
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than std Rad when the ranking criterion is the correlation value between the feature value and the
ovarian mass label.
The correlation between each two significant features can be seen in Table 3.3. The values in this
table show that rHbT has a rather high correlation with all the image features, the lowest one being
the std Rad, with a correlation value of 0.46. Moreover, all the image features except for std Rad
are highly correlated. Among the image features, contrast has the highest correlation with std Rad,
with a Spearman’s rho of 0.13.
Table 3.2: Ordering the significant features for distinguishing benign/normal ovarian masses
from epithelial cancer, based on their p-values (left) and Spearman’s rho between each
feature and the class label.
Ordering features based on p-value
Feature
p-value
rHbT
<0.001
sO2
<0.001
0.5 MHz SI (PAT)
0.003
Area
0.006
Contrast
0.008
std Rad
0.008
Correlation
0.01

Ordering features based on correlation
Feature
|Spearman’s rho|
rHbT
0.64
sO2
0.61
std Rad
0.52
0.5 MHz SI (PAT)
0.46
Area
0.36
Correlation
0.28
Contrast
0.26

Table 3.3: Spearman’s cross correlation between each two features in the set of significant
features for distinguishing benign/normal ovarian masses from epithelial cancer.

sO2
rHbT
0.5 MHz SI
Area
(PAT)
Contrast
Correlation

rHbT

0.5 MHz SI
(PAT)

Area

Contrast

Correlation

std Rad

0.39

0.15
0.36

0.35
0.8
0.51

0.19
0.6
0.46
0.61

0.19
0.63
0.47
0.68
0.97

0.28
0.46
0.05
0.11
0.13
0.09

To train classifiers, we started constructing our model by using the feature with the highest
correlation with the class label. Then we added the other significant features one by one until we
found that adding features does not improve the classification performance. Figure 3.5 (top row)
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shows the ROCs for the training and testing data sets using a GLM model. The top left shows that
the AUC for the training data set is 0.99 when rHbT, sO2 and 0.5 MHz SI (PAT) are used for the
classifier construction. For the testing data set (top right), however, the highest value of AUC is
achieved when rHbT and sO2 features are employed for the classification (AUC=0.93). Adding
0.5 MHz SI (PAT) or std Rad to the feature set decreases this value by 0.02 and 0.05, respectively,
and further inclusion of any of the other significant features results in an additional decrease in the
AUC values (not shown in the plot).
The SVM classifier performance in differentiating benign/normal lesions from epithelial cancers
for the training and testing data sets is shown in Figure 3.5 (bottom row). As can be seen, in this
case, unlike for GLM, adding 0.5 MHz SI (PAT) to the features set of “rHbT, sO2” increases the
value of the AUC from 0.93 to 0.94. However, similar to the GLM classifier, inclusion of std Rad
in the features set decreases the AUC value for the testing data set.
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Figure 3.5: ROCs for the training (left) and testing (right) data sets and the associated AUCs for
different feature sets, using the GLM (upper row) and SVM (lower row) classifiers. The
classifiers distinguish benign/normal from epithelial cancers.

Classification of benign/normal ovaries and all types of tumors
We then had epithelial cancer and other neoplasm types in one group and compared the calculated
features of this combined group with those of benign/normal group. Only four features, i.e., sO2,
rHbT, 0.5 MHz SI (PAT), and sdt Rad, among all the calculated features were statistically
significant (p<0.05). Box-plots of these features are shown in Figure 3.6. The sO2 and rHbT values
for the “epithelial and other cancers” group are respectively lower and higher than those of the
benign/normal group. The 0.5 MHz SI (PAT) value is generally higher for cancerous ovaries than
for of benign/normal ones, which indicates more low frequency components for cancers. Moreover,
the std Rad is lower for cancer than for normal ovaries, because the vascular distribution of the
benign mass is more scattered than in tumors (higher standard deviation).
In Table 3.4, these four significant features are ordered based on their p-values (left), as well as on
the value of Spearman’s rho (right). In this case, both ranking criteria determine sO2 to be the most
valuable parameter. Also note that among the three significant features selected for model
construction, std Rad and rHbT are the most well correlated pair (Spearman’s rho = 0.47), while
Spearman’s rho between std Rad and 0.5 MHz SI (PAT) is the lowest (0.02), as shown in Table
3.5.
Figure 3.7 (top) shows the ROC plots for training and testing data sets when a GLM classifier was
employed to distinguish the benign/normal group from all types of ovarian cancers. As can be seen,
sO2 alone results in training and testing AUC values of 0.90, while considering rHbT as the only
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feature in the features set generates lower training and testing AUCs (0.83 and 0.84, respectively).
The highest testing AUC value is obtained when the feature set includes just sO2 and rHbT (0.92).
Note that although adding either 0.5 MHz SI (PAT) or std Rad improves the classifiers
performance for the training data set, it reduces the testing AUC from 0.92 to 0.87.

Figure 3.6: Box plots of the significant features for two groups of ovaries. For each feature, the
p-value between the two groups is shown.

Table 3.4: Ordering the significant features for distinguishing benign/normal ovarian
masses from epithelial and other ovarian cancers, based on their p-values (left) and
Spearman’s rho between each feature and the class label.
Ordering features based on p-value
Feature
p-value
sO2
<0.001
rHbT Mean
0.001
0.5 MHz SI (PAT)
0.02
std Rad
0.03

Ordering features based on correlation
Feature
|Spearman’s rho|
sO2
0.64
rHbT Mean
0.54
0.5 MHz SI (PAT)
0.41
std Rad
0.36

Table 3.5. Spearman’s cross correlation between each two features in the
significant features set for distinguishing benign/normal ovarian masses
from epithelial and other ovarian cancers.
sO2
rHbT Mean
0.5 MHz SI
(PAT)

rHbT Mean
0.36

0.5 MHz SI (PAT)
0.16
0.30
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std Rad
0.2
0.47
0.02

The ROC plots for the training and testing data sets using the SVM classifier to differentiate the
benign/normal ovary group for all types of cancers are shown in Figure 3.7 (bottom) and compared
for different feature sets. As with GLM, the best performance of the SVM model is achieved when
sO2 and rHbT are the only features employed in the features set (training and testing AUCs of
0.95 and 0.93, respectively). Moreover, adding 0.5 MHz SI (PAT) feature decreases the testing
AUC of the SVM classifier by 0.04, but it does not have much influence on the AUC of the training
data set. Finally, inclusion of std Rad decreases the AUC values for both the training and testing
data sets.

3.3.3 Classification by exclusion of functional features in the features set
Next, we evaluated the performance of the classifiers assuming that PAT functional features were
not available. As discussed before, based on the correlation values between different features, we
divided the non-functional PAT features into three groups. The first group contains the single
significant spectral feature of 0.5 MHz SI (PAT). PAT image area, contrast, and correlation are
included in the second group. The third group is made of std Rad feature only.
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Figure 3.7: ROC for the training (left) and testing (right) data sets and the associated AUCs for
different feature sets, using the GLM (upper row) and SVM (lower row) classifiers. The
classifiers distinguish benign/normal ovarian masses from epithelial cancer and other neoplasms.

The ROC plots for the training and testing data sets using the SVM classifier to differentiate the
benign/normal ovary group for all types of cancers are shown in Figure 3.7 (bottom) and compared
for different feature sets. As with GLM, the best performance of the SVM model is achieved when
sO2 and rHbT are the only features employed in the features set (training and testing AUCs of
0.95 and 0.93, respectively). Moreover, adding 0.5 MHz SI (PAT) feature decreases the testing
AUC of the SVM classifier by 0.04, but it does not have much influence on the AUC of the training
data set. Finally, inclusion of std Rad decreases the AUC values for both the training and testing
data sets.
Classification of benign/normal ovaries and epithelial tumors
First, we developed classifiers to distinguish benign/normal masses from the epithelial cancer
group using PAT spectral and image features. Figure 3.8 shows the training and testing ROCs for
these new GLM (top) and SVM (bottom) classifiers. The SVM classifier shows better performance
(training and testing AUC of 0.94 and 0.92) when the feature set includes 0.5 MHz SI (PAT), area,
and std Rad. Note that we have not used any features from the second group (including area,
contrast, and correlation) to develop the GLM classifier, since no feature in this group improved
the testing AUC of the GLM classifier.
Classification of benign/normal ovaries and all types of tumors
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Finally, we distinguished the benign/normal group from epithelial and other types of neoplasms
by using GLM and SVM classifiers without PAT functional features. The training and testing ROC
plots for the GLM (top) and SVM (bottom) are shown in Figure 3.9. The performances of the
classifiers are moderate in this case, and the highest testing AUC is achieved when 0.5 MHz SI
(PAT), std Rad, and contrast are included in the feature set and an SVM model is used to classify
the data. Even so, the testing AUC value in this case is just 0.84.

Figure 3.8: ROC for the training (left) and testing (right) data sets and the associated AUCs for
different feature sets, using the GLM (upper row) and SVM (lower row) classifiers. The
classifiers distinguish benign/normal ovarian masses from epithelial cancers. Functional features
are not included in the features set.

45

Figure 3.9. ROC for the training (left) and testing (right) data sets and the associated AUCs for
different feature sets, using the GLM (upper row) and SVM (lower row) classifiers. The
classifiers distinguish benign/normal ovarian masses from epithelial cancers and other
neoplasms. Functional features are not included in the feature set.

3.4 Discussion and Summary
In this study, 22 out of the 24 patients have CA-125. Thus, it could be useful to analyze the effect
of this parameter on our classification performance. However, because the value of CA-125 is
patient-dependent (one number for each patient) rather than ovary-dependent, each patient should
be considered as one independent sample. This would decrease the total number of available
independent samples from 39 to 22, not adequate to train and test our classifiers. The effect of this
parameter on the performances of the classifiers will be evaluated in future studies when more
patients’ data are available.
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Besides the PAT spectral and functional features, US spectral features were also evaluated in this
study. As demonstrated by Lizzi et al [27], the SS of the US spectrum is dependent on the sizes of
the scatterers and the attenuation of the medium, while its SI is a function of the size, concentration,
and acoustic impedance of the scatterers relative to the background medium. Finally, the MBF of
the US spectrum is related to the attenuation of the medium, and the size, concentration, and
impedance of the scatterers relative to the medium. The US spectral features were not reported in
this study because for this feature set, a statistical difference was not found between the
benign/normal masses and epithelial cancers (p>0.05). We will continue to evaluate the diagnostic
values of US spectral features in future studies wen more patients’ data are available.
The textural features of the PAT image proved useful in some of the classifiers in this study.
Among these features, contrast helpfully quantifies the local variations in the PAT images. When
intensity varies significantly from one pixel to another, the contrast values are very large.
Correlation is a measure of the dependence among neighboring pixels, and energy represents the
local uniformity of the pixel values. A higher similarity in pixel values results in larger energy
values. Finally, homogeneity determines the local homogeneity in the image. When there are small
local variations in the image, the homogeneity is large.
We were interested in distinguishing normal/benign ovarian masses from the ovaries with
epithelial cancers. GLM and SVM classifiers were designed to specifically distinguish this
difference. The best performance of an SVM classifier, a testing AUC of 0.94, was achieved when
rHbT, sO2, and 0.5 MHz SI (PAT) were used in the features set. For the GLM classifier, the highest
testing AUC was 0.93, when rHbT and sO2 were employed as the input features. When functional
features were excluded from the classification procedure, the best testing AUC (0.92) was
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associated with an SVM classifier which was trained using the 0.5 MHz SI (PAT), area, and std
Rad features.
Photoacoustic features were also employed to differentiate patients with normal/benign ovaries
from patients with ovarian cancers, either epithelial or other neoplasms. In that case, the SVM
classifier also performed slightly better than GLM. The testing AUC for these classifiers were 0.93
and 0.92, respectively. For both classifiers, using sO2 and rHbT features in the feature set resulted
in the highest testing AUC, and including other features decreased their performance. When
functional features were excluded from analysis, the performances of the classifiers were moderate
(best testing AUC = 0.84 using an SVM classifier). In summary, these results demonstrate that
functional, spectral and imaging features obtained from photoacoustic imaging can
comprehensively classify human ovarian cancer.
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Chapter 4: Sliding multi-pixel method to
improve oxygen saturation estimation using
photoacoustic tomography
4.1 Introduction
Ovarian cancer remains the deadliest of all the gynecological malignancies. According to the
American Cancer Society, 21,750 women in the US will be diagnosed with ovarian cancer in 2020,
and 13,940 deaths will be reported [1]. Due to a lack of effective screening tools, only 20-25% of
ovarian cancers are diagnosed early. A recent update from the U.S. Preventive Services Task Force
concluded that major trials of promising ovarian cancer screening tools have null findings to date
among healthy average-risk women, and there are considerable harms associated with screening,
which include major surgical complications in women found to have no cancer [2]. Women with
a screening abnormality generally undergo prophylactic bilateral salpingo-oophorectomy [3-5],
which can result in morbidity and mortality from premature menopause, including accelerated
bone loss and cardiovascular death [6]. Thus, there is an urgent need to develop better and more
sensitive tools to effectively evaluate the ovary.
Current screening modalities include bimanual pelvic examination and transvaginal ultrasound
(US), as well as assessment of cancer antigen 125 (CA125) serum marker levels, which are
associated with a high false-positive rate [2,8]. Conventional MRI and diffusion-weighted MRI
are useful follow-up modalities for investigating sonographically indeterminate adnexal masses
[9]. Using MRI to measure sO2 for ovarian tumor assessment has not been well studied and is
potentially valuable for future research. CT has been historically preferred for the pretreatment
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evaluation of ovarian cancer to determine both the extent of the disease and the optimal surgical
treatment [10]. FDG-PET/CT can measure residual or recurrent disease and also help select the
surgical treatment [11]. However, FDG-PET has limited value in localizing lesions in the early
stages of ovarian cancer [12].
In the past decade, with advances in lasers, ultrasound transducers, and tomographic reconstruction
techniques, photoacoustic imaging or photoacoustic tomography (PAT) has seen an immense
growth, providing high spatial resolution same as ultrasound and functional information at depths
ranging from several millimeters up to several centimeters [13-19]. PAT is a hybrid imaging
technology that uses a short-pulsed laser to excite the tissue. Acoustic (or photoacoustic) waves
are then generated from thermoelastic expansion due to a transient temperature rise and are
measured by US transducers. PAT image contrast is related to tissue optical absorption properties
and therefore tumor vasculature or tumor angiogenesis. Oncologic targets of PAT to date include
breast cancer [20-28], prostate cancer [29, 30], skin cancer [31], thyroid cancer [32], colon cancer
[33], and ovarian cancers [34-35]. Our limited data have indicated that high grade stage I invasive
ovarian cancers show a higher hemoglobin or vasculature content and a lower sO2 [34].
sO2, an indicator of tumor metabolism and therapeutic response, is one important diagnostic
parameter measured by PAT. To compute sO2, PAT data are acquired at multiple wavelengths,
then used to solve linear equations that relate the PAT signals to the oxy and deoxyhemoglobin
concentrations at each pixel in the region of interest (ROI), simultaneously obtaining the
concentrations of these chromophores at that pixel. This method of calculating sO2, named “linear
unmixing”, has been utilized in many studies [36-45]. In this study, for 49 ovarian masses from
33 patients, we present sO2 maps computed using this method. However, to mitigate the effect of
the measurement errors (e.g. spatial and temporal variations in light fluence, system noise, and
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motion), we replace the value of each pixel with the average of the values of 100 pixels of 1.0 mm
by 1.0 mm in size around it before solving the linear equations. The estimated sO2 maps calculated
using this method, along with rHbT mean value and PAT spectral features, are used to develop
support vector machine (SVM) models. We demonstrate with a considerable patient population
that a combination of PAT features with the radiologists’ diagnostic score, can significantly
improve diagnostic accuracy, achieving an area under the receiver operating characteristic curve
(ROC) of 0.93 on the testing data set.

4.2 Materials and methods
4.2.1 Phantoms
To evaluate the accuracy of our sO2 estimation, we prepared five blood tube phantoms, with sO2
values of 24.9%, 44.2%, 64.9%, 83.9%, and 97.6%. The red blood cells (RBCs) were collected
from healthy volunteers and were mixed with 60% saline water inside a hypoxia chamber with a
temperature/humidity control. Each blood sample with the desired sO2 value was produced by
controlling the amount of oxygen and nitrogen in the chamber. The sO2 value of each blood
sample was calibrated using an ABL90 FLEX Radiometer. This value was considered as the
calibrated sO2 value in the phantom study.
After each blood sample was prepared, it was injected into a 3 mm diameter tube, which was then
tightly capped in the chamber in order to prevent the room oxygen from affecting the sO2 of the
blood sample. Each tube was sequentially positioned at a progression of depths from 1 to 5 cm,
with a step size of 0.5 cm, in a homogeneous Intralipid® solution with calibrated absorption and
reduced scattering coefficients of 0.02 and 4 cm-1, similar to the optical properties of soft tissue.
The PAT/US system was used to collect data from each blood tube at each depth and at
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wavelengths of 730, 780, 800, and 830 nm. To prevent motion during the data acquisition, the
transducer was fixed to a post. The acquired PAT data were employed to calculate the sO2 maps
inside the blood tubes, using linear unmixing (described in 4.2.4). Finally, the mean sO2 value at
each depth was calculated by taking an average over all the pixels with sO2 values greater than
zero.

4.2.2 Patients
The study protocol was approved by the institutional review board and was compliant with the
Health Insurance Portability and Accountability Act. A total of 40 patients with ovarian masses
gave informed consent and participated in this study from February 2017 to November 2018. Out
of these patients, 7 were excluded from the data analysis: 3 patients due to PAT/US system
problems, 2 patients without any ovarian masses found at the time of imaging, and 2 patients with
deep ovarian masses in the range of 6 to 7 cm from the probe. In 18 of the remaining 33 patients,
both ovaries were imaged. Among the other 15 patients, only one suspicious ovary (with
pathological evaluation available) was imaged and surgically resected. Thus, the total number of
the imaged ovaries was 51, out of which two ovaries were not considered in our analysis because
pathology data was not available for them (Figure 4.1).
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Figure 4.1: Flowchart for inclusion and exclusion of study participants, including reasons for
exclusion.

In Table 4.1, the imaged ovaries in this study have been divided into four main categories of
invasive epithelial ovarian cancer, other neoplasm, benign ovaries, and normal ovaries. On the
right side of the table, each mass type has been divided into more subgroups. The number of
ovaries belonging to each subgroup as well as the information about the mass size and depth is
also provided in the table.
Table 4.1: Lesion Characteristics (33 patients with 49 ovaries: average age of 56 years, range
33-87 years)
Invasive epithelial ovarian cancer

high grade serous carcinoma (n=7), endometrioid
carcinoma (n=3) (average size, 9 cm; size range, 2.8 20 cm; average depth, 3 cm; depth range, 2.2 - 4.3 cm)

Other neoplasm

serous borderline (n=2) tumor, Sertoli-Leydig cell tumor
(n=1) (average size, 11.1 cm; size range, 4.5 - 19.2 cm,
average depth, 3.6 cm; depth range, 2.6 - 5.5 cm)

Benign ovaries

fibrothecoma (n=1; size, 14 cm; depth, 1.9 cm), mature
teratoma (n=1; size, 6 cm; depth, 3.1 cm), serous or
mucinous cystadenoma or cystic endometriosis (n=17;
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average size, 10 cm; size range, 1.8 – 3.7 cm; average
depth, 2.7 cm; depth range, 0.7 - 7.4 cm), complex or
simple cysts (n=10; average size, 4.3 cm; size range, 3 7.6 cm; average depth, 2.7 cm; depth range, 0.6 – 5.5
cm), benign leiomyoma (n=1; size, 5.5 cm; depth, 1.8
cm), fibrosis and cyst (n=1; size, 4 cm; depth, 1.9 cm)
Normal ovaries

no histopathological abnormalities (n=5; average size,
2.5 cm; size range, 2.1 -2.8 cm; average depth, 1.6 cm;
depth range, 0.6 - 2.6 cm)

4.2.3 Ovarian mass ranking
For each patient, one attending radiologist evaluated all available images of x-ray CT, MRI, prior
US from the patient’s medical record as well as the real-time US images. Based on this
information, the radiologist provided a score in a range of 1 to 5 for each ovarian mass before the
co-registered photoacoustic and ultrasound exam. Scores 1 and 2 are normal, 3 is likely benign, 4
is suspicious for malignancy, score 5 is highly suspicious for malignancy. For the data analysis,
we categorized scores 1 and 2 as normal, score 3 as benign, and 4 and 5 as malignant. This mapped
feature is referred to as the radiology ranking (Rad rank) in this manuscript.

4.2.4 PAT functional features
To calculate the PAT functional features, i.e. rHbT and sO2, we need to estimate relative oxy and
deoxy hemoglobin concentrations, 𝐶̂𝑜𝑥𝑦 (𝑟, 𝜃) and 𝐶̂𝑑𝑒𝑜𝑥𝑦 (𝑟, 𝜃), which can be obtained using
the linear unmixing approach [36-45]. Briefly, we find a solution at each pixel by solving a linear
least square problem with the constraint of non-negative solutions as:
Object F= argmin ‖𝑔 − 𝐻𝑓‖2 ; 𝑓 ≥ 0 ,
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Eq. (4.1)

where g represents measurements at 4 wavelengths used, H is the known matrix consists of
extinction coefficients of the four wavelengths, and f represents the 𝐶̂𝑜𝑥𝑦 (𝑟, 𝜃) and
𝐶̂𝑑𝑒𝑜𝑥𝑦 (𝑟, 𝜃) that need to be estimated.
ε𝑜𝑥𝑦−730
𝑃0𝑛−730
ε𝑜𝑥𝑦−780
𝑃
g= [ 0𝑛−780 ], H= [ε
𝑃0𝑛−800
𝑜𝑥𝑦−800
ε𝑜𝑥𝑦−830
𝑃0𝑛−830
f = [𝐶̂𝑜𝑥𝑦 (𝑟, 𝜃)

ε𝑑𝑒𝑜𝑥𝑦−730
ε𝑑𝑒𝑜𝑥𝑦−780
ε𝑑𝑒𝑜𝑥𝑦−800 ] , 𝑎𝑛𝑑
ε𝑑𝑒𝑜𝑥𝑦−830

𝐶̂𝑑𝑒𝑜𝑥𝑦 (𝑟, 𝜃)].

The subscripts 730, 780, 800, and 830 in the above equations denote the wavelengths used in this
study. The rHbT is then simply calculated by summing them. Furthermore, sO2 is estimated by
dividing the relative oxyhemoglobin by rHbT.
In our previous studies [34,35], we calculated the functional features at each single pixel by solving
Eq. (4.1). We then applied a spatial filter to improve the sO2 image quality. However, due to the
measurement errors arise from spatial and temporal variations in light fluence caused by tissue
optical absorption and scattering heterogeneities, system noise, and motion, solving a linear
equation at each single pixel might not be a robust method for finding the functional features. To
mitigate this problem, we replaced the value of the envelope data in each pixel by the mean of the
envelope at an area around it with a size of 10×10 pixels. We named it multi-pixel method. Thus,
for each pixel, the area of 1.0 mm × 1.0 mm is chosen so that the smaller pixel is in the center of
the 10×10 pixels.
We also investigated using Gaussian and Lorentzian algorithms as spatial filters to smooth the
PAT data before calculating the sO2 maps. The size of each filter was fixed at 1.0 mm × 1.0 mm
(10 pixels by 10 pixels), the same as the size in the multi-pixel method. To take advantage of the
spatial filter’s ability to mitigate measurement errors without significantly impairing the spatial
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resolution, we had to assign appropriate values to the parameters of the filters. The filter parameters
that we adjusted were the standard deviation of the Gaussian filter and the full width at half
maximum (FWHM) of the Lorentzian filter, both indicated by “sigma” in this manuscript. Small
standard deviations of the Gaussian filters or small FWHMs of the Lorentzian filters give too much
weight to the pixels in the center of each kernel, neglecting the contributions of the pixels around
it. The resulting sO2 maps are undesirably similar to maps without any spatial filters. On the other
hand, if a very large standard deviation or Lorentzian parameter is chosen, all the pixels in the
kernel will have almost the same weight. In this case, there will be no difference between the
generated sO2 maps calculated using these filters and those estimated using sliding multi-pixels.
Because our multi-pixel kernel size is 10 pixels, we decided to assign half of this value (5) to the
standard deviation of the Gaussian filter and Lorentzian filter parameter.
After finding the sO2 map, we constructed its histogram and calculated the histogram features
(mean, standard deviation, skewness, kurtosis, energy, and entropy). Among these features, three
(mean, skewness, and energy) showed significant differences between the benign and malignant
ovarian groups.
To compare the robustness of the different smoothing methods, we calculated the value of the
squared norm of the normalized residuals (for simplicity, called the normalized residual
throughout this manuscript) at that pixel. To find this parameter at each pixel, after solving the
linear optimization of Eq. (4.1), we normalized each element of (𝑔 − 𝐻𝑓) by the summation of all
four wavelengths of g at that pixel, thereby removing the dependency of the residuals on the
magnitude of g. Then we calculated the normalized residual at that pixel as
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𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑅𝑒𝑠𝑖𝑑𝑢𝑎𝑙 = (𝑔 − 𝐻𝑓)𝑇𝑛 × (𝑔 − 𝐻𝑓)𝑛 ,

Eq. (4.2)

where superscript T indicates the transpose of the matrix, and subscript n means the matrix has
been normalized pixel by pixel after optimization. The better the data fits the model, the lower the
value of the normalized residual will be. Thus, we use this parameter to evaluate sO2 robustness.

4.2.5 Statistical analysis, feature selection, and classification
Each investigated ovarian mass in this study was included in either the benign/normal group (36
ovaries) or the malignant group (13 ovaries). To evaluate the difference between these two groups,
a two-tailed t-test with the assumption of an unequal variance between the two groups was
performed on each available feature. A feature with a p-value equal to or less than 0.05 was
considered significant. Moreover, a random forest model was employed to rank the importance of
each feature. The importance of each feature is calculated by averaging the Gini impurity at each
node of the forest where that feature is used. Scikit-Learn, a module in Python, was used to
calculate the features importance. Further information about feature selection using random forest
models is found in Ref [49].
Support vector machine (SVM) models were trained to distinguish benign/normal ovaries from
those with malignant tumors. Models were developed for three subsets of uncorrelated significant
features extracted from all the ovaries: radiology ranking (Rad rank) alone; uncorrelated PAT
features (sO2 mean, and rHbT mean, spectral intercept (SI)) alone; and the combination of
uncorrelated PAT features and the radiologist’s ranking (sO2 mean, rHbT mean, SI, and Rad rank).
Each model was trained 100 times, each time using a random selection of 2/3 of the available
dataset for training, and the rest of the data was reserved for testing. At each iteration the ROC of
the training and testing data sets were computed. The mean receiver operating characteristic (ROC)
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curve and the area under the curve (AUC) over all iterations were then calculated for the training
and testing data sets. The model which provided the highest AUC value for the testing data set was
considered as the best model. Note that, the AUC of the training data set was found just to monitor
the classifiers for overfitting (overfitting occurs when training AUC increases, but the testing AUC
does not).
The mean AUC values were also used to calculate the 95% confidence interval (95% CI) for each
constructed model using a binomial formula.

4.3 Results
4.3.1 Ranking by the radiologists
A boxplot of the ovarian mass ranking is shown in Figure 4.5 (a). Note that our expert radiologist
successfully detected all malignant ovaries, but a few benign ovaries were misclassified as
malignant.

4.3.2 sO2 calculation for blood tube phantoms
In Figure 4.2, we demonstrate the accuracy of our sO2 calculations when the medium was filled
with homogeneous Intralipid® solution. The multi-pixel method was used before linear unmixing.
Each column in this figure shows the result for a different blood tube, with its associated calibrated
sO2 value indicated at the top of the column. The images are from experiments in which the tube
was located at a depth of 2.5 cm. Figure 4.3 summarizes the calculated mean sO2 values at different
depths. Each box plot in this figure shows the calculated mean sO2 value at depths from 1 to 5 cm,
with a step size of 0.5 cm. The mean absolute estimation errors at different depths for the blood
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tubes with the calibrated sO2 of 24.9, 44.2, 64.9, 83.9, and 97.6 are 5.6%, 3.8%, 9.8%, 8.7%, and
17.7%, respectively.

Figure 4.2: The co-registered US and sO2 maps for different blood tubes located at the depth
of 2.5 cm in intralipid. Each column indicates the sO2 maps for a blood tube with the
calibrated sO2 value specified at the top of the column. The mean of the calculated sO2 is
above each sub image.

Figure 4.3: Calculated sO2 values vs calibrated values. Each blood vessel was placed in
Intralipid at depths from 1 to 5 cm below the probe surface, in nine successive steps of 0.5 cm
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each. At each depth, the mean sO2 value was calculated. Each box plot summarizes the mean
calculated sO2 at these 9 different depths.

4.3.3 PAT features for patients
In Figure 4.4, the rHbT and sO2 maps and PAT spectral features are compared for a malignant (ad) and a benign (e-h) ovarian mass. Multi-pixel method is used before linear unmixing. In these
figures, the lesion regions are indicated by the dashed rectangles in the overlaid rHbT (color-scale
image) and background US (gray-scale) images. The malignant ovary has a stronger and more
concentrated rHbT map than the benign mass. This difference is also shown in Figure 4.5 (h),
where the box plot of the mean rHbT for all the benign/normal masses is compared with that of
the malignant cases. A significant difference was not observed between these two groups, in terms
of the mean of rHbT maps (p=0.06).
The histogram for each sO2 map is shown below in Figure 4.4 (c) and (g). As can be seen, the
mean sO2 is lower for the malignant group. Also, the histogram of the malignant ovary is skewed
toward the lower values, while the benign ovary has a sO2 histogram skewed towards the higher
values. Furthermore, Figure 4.5 (b) to Figure 4.5 (d) verify the expected conclusion that in terms
of skewness, mean, and energy, the sO2 histograms (e and f) show a significant difference between
the benign/normal and malignant groups. Because the sO2 calculation is very sensitive to the PA
signal to noise ratio (SNR), we have excluded four ovaries with a poor SNR in the final analysis.
For these ovaries, the maximum signal levels at all wavelengths (elements of matrix g in Eq. (4.1))
in the ROI were around the noise level of our system (60 mV). Therefore, performing linear
unmixing on these noisy data led to a non-robust estimation of sO2 in the ROI.
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Finally, in Figure 4.4 (d) and (h), the mean spectra of the PAT beamlines in the ROI along with
their fitted lines are presented for a malignant and a benign ovary, respectively. The malignant
ovaries show a smaller value of SS (more negative) and a larger value of SI (less negative). The
box plots in Figure 4.5 (e) to (g) verify these observations. As demonstrated in Ref [50], the lower
SS in the malignant ovaries is related to the larger size of absorbers that are present in this type of
masses, and the higher SI is associated to the larger size of the absorbers as well as a higher
concentration of them in malignant ovaries.

Figure 4.4: Comparison of PAT functional and spectral features of a malignant ovary (a-d)
with a benign case (e-h). “a” and “e” are the coregistered US and rHbT maps for the two types
of ovarian masses. “b” and “f” show the coregistered US and sO2 map calculated in the ROI
indicated by the rectangles in “a” and “e”, respectively. “The histogram of the sO2 maps are
shown in “c” and “g”. The mean spectra of the beamlines in the ROIs and their fitted lines are
shown in “d” and “h”.
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Figure 4.5: Box plots of the most significant features and rHbT. The p-value from a t-test on
each feature is shown in the associated plot. The number of samples in each group is also
shown below the x-axis of each plot. The sO2 maps were calculated in 10×10 multi-pixels.
The three-digit numbers that follow SI or SS in the plots indicate the optical wavelength at
which the data was acquired.

4.3.4 Spatial filtering methods
We investigated the effect of the three smoothing filters on the calculated sO2 and residual norm
maps. Multi-pixel smoothing used a 10 × 10 pixel window. The standard deviation of the Gaussian
filter and the Lorentzian parameter of the Lorentzian filter were fixed at sigma=5 (see details in
Appendix A). An example of the calculated sO2 and normalized residual maps using different
smoothing methods is shown in Figure 6 for the malignant ovary in Figure 4. As can be seen, the
mean values of the calculated sO2 maps and mean values of the normalized residuals do not change
much when different spatial filter methods are used.
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Figure 4.6: The sO2 (a-c) and the corresponding normalized residual (d-f) maps calculated using
different smoothing methods for the malignant ovary in Figure 4. The multi-pixel size or sigma
for each smoothing method is in the parenthesis in the image title. MP, GS, and LZ in these plots
represent multi-pixel, Gaussian, and Lorentzian smoothing methods, respectively.

We calculated the histogram features of the sO2 maps using different smoothing filters (Figure 7).
The box plots of the malignant and benign/normal ovaries are located separately in these plots,
and the p-values calculated by two-tailed t-tests between the benign/normal and malignant ovaries
are shown in each plot. In terms of p-values, the different smoothing methods generate similar
results, except for the energy of the sO2 maps. For this parameter, unlike the multi-pixel and
Gaussian filters, the Lorentzian filter does not show a statistically significant difference between
the benign/normal and malignant groups (p>0.05). Moreover, the box plots of the benign ovaries
in the sO2-skew and sO2-energy plots calculated using Gaussian method are more spread out than
the associated boxplots for the features calculated using the multi-pixel method. Therefore, for our
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data, the multi-pixel method is a better option than using the other two spatial filters, and it is used
in data analysis throughout this manuscript.

Figure 4.7: Box plots of histogram features calculated by using different smoothing methods. “a”
shows the mean of the sO2 maps, and “b” and “c” are the skewness and energy of these maps,
respectively. MP, GS, and LZ indicate the multi-pixel, Gaussian, and Lorentzian smoothing
methods. The p-values for each method are in the lower right of each plot.

We also calculated the mean residual norm for all the ovarian masses, shown in Figure 4.8. The
average and standard deviation of the mean normalized residual maps using each method are
shown on the right of each plot. Overall, sO2 maps with a slightly lower normalized residual error
are achieved by using the multi-pixel method. Therefore, this method was used for estimation of
sO2 maps in this manuscript.
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Figure 4.8: Box plots of the means of the normalized residual error maps of all ovaries,
calculated using MP, GS, and LZ smoothing. The decimal numbers on the right are the mean ±
standard deviation of all the samples in each box.

4.3.5 Features ranking
As mentioned before, the significance of each extracted feature was evaluated using the Student’s
t-test. These features were then ranked in ascending order, meaning that features with lower pvalues (shorter bar length in Figure 4.9 (a)) were located higher in the ranking. Figure 4.9 (a) shows
the first eight most important features based on the p-value ranking. These eight features were
ranked using a random forest model (explained section 2.7) as well and presented in Figure 4.9
(b). In this plot, unlike the p-value ranking, the longer bars represent more important features.
Note that Rad rank is the most important feature in both rankings. Moreover, although rHbT is
located on the bottom of the ranking in Figure 4.9 (a), the random forest model has ranked it as
the second most important feature. Another interesting point about these plots is that three of the
first four features in Figure 4.9 (a) were highly correlated (sO2-mean, sO2-skew, sO2 -energy),

68

while in the random forest ranking (Figure 4.9 (b)), no correlation was found between each pair of
the first 4 features (The correlation between each two features was evaluated using Spearman’s
method). This is an important consideration when developing classifiers as highly correlated
features lead to overfitting our model. A second point to keep in mind when designing classifiers
to decrease the chance of overfitting is that the number of features that is used for training should
2

be less than one-tenth of the training size [51]. The training size in this study was (3 × 49 ≈ 33),
so we did not use more than four features. As the first four features in the random forest ranking
are not correlated, designing the classifiers based on this ranking seems to reduce the chance of
overfitting.

Figure 4.9: Feature ranking based on (a) p-value. (b) random forest importance. In (a), more
significant features have shorter bar length and located higher in the ranking. In (b), more
significant features have longer bars and located higher in the ranking.

4.3.6 Classification
We developed SVM classifiers to distinguish between “malignant” and “benign/normal” groups.
In this case, the data set was randomly divided into 2 groups. The first group included two-thirds
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of the data used for training, and the rest of the data was employed for testing the classifiers. To
lower the chance of overfitting, this process was repeated 100 times.
Four SVM models were trained in this study. The first model was trained using the single radiology
feature (Rad rank). The second one was trained using 3 most important PAT features based on the
random forest ranking (rHbT, sO2 mean, and SI 730). The third model was trained using the
combination of the features used in the last two models. Finally, in the last model, rHbT was
removed from the features set. For each model, the 95% confidence of interval (CI) was computed.
Moreover, the mean ROC of each of the training and testing data sets for these four models were
calculated and are shown in Figure 4.10. In the legend of each plot, the left-hand side of each
equation represents the features set employed to train the classifiers and the decimal numbers on
the right-hand side are the mean AUC values and the 95% CI associated with the ROC of that
classifier. As can be seen on the plots, when just radiology ranking was used to train the SVM
classifier, a mean AUC value of 0.85 (95% CI: 0.81 - 0.89) was achieved. On the other hand, the
performance of the classifier was not impressive when just PAT features were used to train the
classifiers (mean testing AUC = 0.77 (95%CI: 0.73– 0.81). By combining the radiology and PAT
features, a superior AUC value of 0.92 (95%CI: 0.89 – 0.95) on the testing data set was achieved.
However, when rHbT was removed from the features set, the performance of the SVM classifier
on the testing data set improved to 0.93 (95% CI: 0.90 – 0.96).
Two of the thirteen malignant ovaries imaged in this study were serous borderlines, and another
one was sertoli-Leydig cell tumor. These types of malignancies are considered low-grade cancers.
The estimated sO2 maps for these masses were similar to those for high-grade cancers. However,
their rHbT maps and spectral features were close to the ovaries in the benign group. Without these
outliers, performing the t-test on rHbT resulted in a p-value of 0.03. However, including these
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outliers, p-value between all malignant lesions and the benign group is marginal significant
(p=0.06). As these ovaries have some features similar to the malignant group and some others
close to the benign group, performing a multi-class classification to divide the ovaries into 3 groups
of high-grade cancers, low grade cancers, and benign ovaries might be a better choice. However,
as we currently have a very limited number of the low-grade cancers (n=3), it is not feasible to
train such a model at this time.

Figure 4.10: The mean ROCs, AUCs, and 95% CI of the four SVM models developed to
classify normal/benign ovaries and malignant ovaries for training (top) and testing (bottom)
data sets.
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To evaluate the contribution of other significant sO2 features (skewness and energy), we combined
these features with other types of extracted features and constructed new models. Each model was
developed once by including rHbT in, and a second time, by excluding this feature from the
features set. The performances of different classifiers are summarized in Table 4.2. By comparing
the testing AUC values, we concluded that rHbT did not improve the performance of any of the
constructed models which could be due to the inclusion of the three low grade tumors in the cancer
group.
Table 4.2: AUC of models constructed using different sO2 features, with and without rHbT
Features (predictors)

̅̅̅̅̅̅ (0.95% CI)
Training 𝑨𝑼𝑪

̅̅̅̅̅̅ (0.95% CI)
Testing 𝑨𝑼𝑪

sO2 mean, SI730, Rad rank

0.95 (0.93 – 0.97)

0.93 (0.90 – 0.96)

sO2 mean, SI730, Rad rank, rHbT

0.95 (0.93 – 0.97)

0.92 (0.89 – 0.95)

sO2 skew, SI730, Rad rank

0.95 (0.93 – 0.97)

0.92 (0.89 – 0.95)

sO2 skew, SI730, Rad rank, rHbT

0.95(0.92 – 0.97)

0.92 (0.89 – 0.95)

sO2 energy, SI730, Rad rank

0.93 (0.90 – 0.96)

0.92 (0.89 – 0.95)

sO2 energy, SI730, Rad rank, rHbT

0.93 (0.91 – 0.96)

0.90(0.87 – 0.93)

4.4 Discussion and Summary
In this work, we used the linear unmixing method to calculate sO2 values from phantom and
clinical PAT data. In our earlier publication [35], the sO2 maps were calculated by solving linear
equations independently for every single pixel. A spatial filter was then applied to smooth the sO2
maps. Here, before the linear equations are solved, the value of the envelope data at each pixel is
replaced with the average value of the envelope data for 100 surrounding pixels, which makes the
results more robust to measurement errors. Additionally, whereas our earlier study computed only
the mean sO2 from each sO2 map, here we calculated six histogram features of the sO2 maps
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(mean, skewness, energy, variance, kurtosis, entropy), and the first three features were statistically
significant. Furthermore, our earlier study ranked features based on their p-values estimated from
t-tests. Here, a random forest model has been utilized for ranking the features, reducing the chance
of overfitting. Finally, the radiology score has been used in this study, which is a significant step
toward the clinical translation of the technology.
We demonstrated the accuracy of estimating the sO2 for different calibrated blood tube phantoms
embedded inside a homogeneous Intralipid medium. Whole blood consists of a substantial number
of impurities, including enzymes that cause blood coagulation. Therefore, we followed the
standard process of centrifuging whole blood in order to collect red blood cells (RBCs). The RBCs
were diluted with saline water and placed inside a hypoxia chamber, where oxygen and nitrogen
concentrations were controlled to produce the desired sO2 condition. A 60% saline solution was
used to dilute the RBCs and avoid saturation of the oximeter used to calibrate each blood sample.
Since the goal was to estimate sO2 of the blood sample using PAT, diluting the RBCs with 60%
saline provided strong PA signals without affecting the results.
We also calculated sO2 using clinical data. The calculated sO2 and rHbT maps, along with SI and
Rad rank, were then used to construct different SVM models. The highest AUC value on the testing
data set was found for the model constructed from sO2 mean, SI730, and Rad rank. In our earlier
publication [35], we developed two classifiers, models A and B.

Model A distinguished

“benign/normal” masses from those with “epithelial ovarian cancers”. For the testing data, the best
AUC of 0.94 was achieved using an SVM classifier. Model B distinguished “benign/normal”
lesions from those with “epithelial ovarian cancers and other types of tumors”. With this model,
we achieved a best testing AUC of 0.93. In the present manuscript with a larger sample size, we
have developed one classifier, model C, which differentiates “benign/normal” masses from
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“epithelial cancers and other types of tumors”. With the addition of the radiology scores, an AUC
of 0.93, closely similar to that of model B, was also achieved. In practice, model C has more
translational potential because it integrates conventional imaging with PAT functional imaging
features.
Depleted oxygen and glucose in the microenvironment of ovarian cancer limits the potential for
cellular metabolic plasticity, which has been appreciated as playing a key role in cancer
progression and chemoresistance [52]. In a recent study [53], Qiu et al. reported the first evidence
that levels of a natural antisense transcript of hypoxia-inducible factor 1 (aHIF) were increased in
epithelial ovarian cancer (EOC) tissues and were upregulated by hypoxia in EOC cells. Functional
data revealed that aHIF knockdown accelerated cell apoptosis under hypoxia and inhibited EOC
tumorigenesis and tumor growth in-vivo. Photoacoustic tomography provides blood sO2, which is
related to the tumor oxygen microenvironment and may have a greater role in ovarian cancer
diagnosis and assessing chemotherapy response.
Our ovarian mass reader evaluation is a single institution experience, and the ovarian mass ranking
was performed by two highly experienced radiologists with over 55 years of combined expertise
in pelvic ultrasound. Their experience and breadth in pelvic imaging does not reflect the wider
radiology community and will not be the case as PAT gets integrated in the clinical imaging
armamentarium. In fact, we anticipate that the addition of PAT to ovarian mass imaging may bring
the confidence and accuracy of a general radiologist into the realm of a specialist.
Currently, there are limitations of the photoacoustic technique. First, the typical penetration depth
of PAT is about 5 cm. In cystic ovarian tissue, however, the PAT penetration depth may reach 6
to 7 cm. We were able to image more than 95% of the ovaries at these imaging depths. A second
limitation is the assumption of wavelength-independent fluence in the linear unmixing method.
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Quantitative sO2 calculation without this assumption has been a hot topic in the field of
photoacoustic tomography in recent years, and several methods, including deep learning models
and model-based algorithms, have been proposed [54-59]. Nevertheless, although interesting
results have been observed for simulation and phantom data, applying these methods to clinical
data remains a challenge.
In summary, our study with a considerable patient population has shown for the first time that sO2
and its distribution can play a significant role in ovarian cancer diagnosis. Combined with the
diagnosis of radiologists, the overall accuracy of identifying both high grade epithelial ovarian
cancer and low-grade ovarian tumor can achieve an AUC of 0.93. A large clinical study is
currently underway to validate these initial findings.
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Chapter 5: Quantitative photoacoustic
tomography using two-step optimization
method for estimation of properties of blood
samples
5.1 Introduction
Photoacoustic tomography (PAT) is based on the generation of ultrasound waves by a short pulse
laser. This modality can simultaneously provide decent imaging contrast as well as resolution [15]. It also has the potential of obtaining functional information about the tissue. However, accurate
estimation of the functional parameters using photoacoustic imaging is challenging. This is
because of the fact that the detected signals by the transducers are not just a function of the
absorption coefficient of the target, but rather a multiplication of this parameter with some other
tissue and system related parameters.
Recently, our group has demonstrated the potential of photoacoustic tomography in ovarian and
colon cancer diagnosis [6-10]. In those studies, the rHbT was calculated using the PAT beam data
at four wavelengths. To calculate this parameter, the value of optical fluence on the surface of the
tissue was employed as this value was not available at the other locations in the tissue. Clearly,
this method of approximating the total hemoglobin is crude and cannot be considered as being
related to just the chromophores in the target area. In fact, it is also related to the optical properties
of the background tissue.
One of the barriers in quantitate evaluation of the tissue using photoacoustic tomography is related
to the optical fluence estimation in the tissue [11-14]. One of the most known methods to estimate
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light fluence in the tissue is using radiative transfer equation (RTE). This is an integro-differential
equation, relating the light radiance to the source and the optical properties of the medium and may
be solved using the finite element method (FEM) [15]. When the reduced optical scattering
coefficient of the medium is much higher than its optical absorption coefficient, RTE can be
approximated as the diffusion equation (DE). If the medium is heterogenous, the DE equation can
be solved using a numerical method, such as FEM [16, 17]. In the case of homogenous medium,
a simpler way using green function exists to solve DE. For 2-D case, the fluence can be found
using Beer’s law: Φ(𝑧) = Φ0 exp (−𝜇𝑒𝑓𝑓 𝑟), where Φ0 is the fluence on the surface, 𝜇𝑒𝑓𝑓 is the
effective attenuation coefficient and r is the distance from the surface of the tissue. Besides these
analytical methods, Monte-Carlo, which is a numerical method, has also been used by some
researchers to deal with the fluence estimation problem in the medium.
In this study, we have started with the simplest case of using Beer’s law to estimate the fluence in
the target area. We have verified this method in the case when blood tube phantoms are located at
different depths in an intralipid medium (with optical properties like human tissue). Then, the
optical absorption coefficients of the blood samples have been found by solving an unmixing
problem using a conjugate-gradient method. These coefficients have been used to estimate the oxy
and deoxyhemoglobin concentrations in the tissue. These concentration values are then employed
to calculate the total hemoglobin (HbT) and sO2 of each blood sample.

5.2 Methods and Materials
Experiment: We have conducted five sets of blood tube experiments with calibrated blood sO2
values of 24.9%, 44.2%, 64.9%, 83.9%, and 97.6% using the co-registered PAT/US system. Blood
from healthy volunteers was processed to collect red blood cells (RBCs) using a protocol of Dr.
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Allan Doctor, WashU Med School. RBCs diluted by adding 60% saline water, referred as “blood”
below, were then prepared inside a hypoxia chamber with temperature/humidity control and a
“glove box” for handling samples in a controlled gas environment (Figure 5.1). Oxygen and
nitrogen gas were controlled to produce the desired sO2 conditions inside the chamber, as
measured by a Radiometer ABL90 Series.

Figure 5.1: The chamber used to control the sO2 values of the blood samples

Figure 5.2. The PAT/US set up used to acquire the PAT signals

Each 3-mm tube was filled with blood of a certain sO2 and tightly capped inside the chamber.
PAT/US experiment was performed immediately after each tube was prepared. sO2 was measured
again with the Radiometer and sO2 change after each PAT/US experiment was less than 2% of the
initially calibrated value. During PAT/US experiment, each tube was imbedded in an intralipid
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scattering medium (μa =0.02-0.03 cm-1 and μs'=4-5 cm-1, typical soft tissue properties) and imaged
at depths from 1 cm to 4 cm with 0.5cm spacing controlled by a stage (Figure 5.2). For each sO2
image obtained at each depth, pixel values greater than zero were averaged to obtain the average
sO2 value.
Data analysis: The initial photoacoustic pressure P0 (λ, r) at any point r =(x,y,z) within the tissue
is proportional to the wavelength-dependent absorption distribution, μa, the fluence Ø (energy/unit
area) distribution, and the Grüneisen parameter, Γ, and can be written as
P0 (λ,r)=ΓØ(λ,r)μa ( λ,r).

Eq. (5.1)

Also, the reconstructed pressure is related to the initial pressure as
P(λ,r)=C0(r)P0(λ,r),

Eq. (5.2)

where C0(r) is the acoustic operator [18]. Due to the very small change in wavelength-dependent
tissue scattering, as well as the constant absorption of water in the narrow wavelength window of
730 nm to 830 nm, the system response and fluence distribution can be approximated as
wavelength-independent. Thus
𝑃 (𝜆, 𝑟) = 𝐶(𝑟)𝜇𝑎 (𝜆, 𝑟), where 𝐶(𝑟)=𝛤𝐶0 (𝑟)Ø(𝑟).

Eq. (5.3)

Considering oxygenated and deoxygenated hemoglobin, HbO and Hb, to be the only dominant
absorbing chromophores in this wavelength range, μa at each wavelength λi can be written as
μa(λi,r)= εHBO(λi )HbO(r)+εHB(λi )Hb(r),

Eq. (5.4)

where εHbO and εHb are the wavelength-dependent molar extinction coefficients of HbO and Hb.
From equations (3) and (4), we have
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𝑃(𝜆𝑖 , 𝑟) = 𝜀𝐻𝐵𝑂 (𝜆𝑖 ) 𝐶(𝑟)𝐻𝑏𝑂(𝑟) + 𝜀𝐻𝐵 (𝜆𝑖 )𝐶(𝑟)𝐻𝑏(𝑟).

Eq. (5.5)

The relative total hemoglobin concentration is given by
𝑟𝐻𝑏𝑇(𝑟) = 𝐶(𝑟)[𝐻𝑏𝑂(𝑟) + 𝐻𝑏(𝑟)].

Eq. (5.6)

rHbT can be computed from multi-wavelength P(λi,r) data. To assess quantitative HbT(r), we need
to estimate 𝐶(𝑟). Furthermore, estimating the local fluence, Ø(r), is challenging because Ø(r) is
also a function of the tissue’s μa and μs'. Another challenge is that the US transducer receives PAT
signals only within a limited field of view. There are several approaches to estimate the fluence
and then quantitatively compute the distribution from P(λ,r) measurements [18]. We have
employed a revised layered-tissue approach similar to the 1-D method reported in Ref. 19 which
approximates the light fluence at depth 𝜌 = √𝑧 2 + 𝑥 2 as

Ø0 𝑒𝑥𝑝−𝜇𝑒𝑓𝑓 ×𝜌 , where 𝜇𝑒𝑓𝑓= √3  a (  a + 𝜇 ′ 𝑠 )

Eq. (5.7)

and Ø0 is the fluence on the tissue surface. For our particular application, with the vagina muscle
wall between the examined ovary and the PAT/US probe and under wide-field light illumination,
this simple 2-D model is more suitable. We formulate the quantitative reconstruction of μa(λ,ρ,ϴ)
as an optimization problem:
f(x) =

2
arg min ( ‖P (λ𝑖 , ρ, ϴ) − Ĉ(ρ, Ɵ) × exp−μeff ×ρ μa (λ𝑖 , ρ, ϴ)‖ )

Eq. (5.8)

̂ (ρ,ϴ),μa (λ,ρ,ϴ)
C

where 𝐶̂ (𝜌, 𝛳) = 𝛤𝐶0 (𝜌, 𝛳) × Ø0 and ϴ is the angle from the central field of view of the US
transducer. We first fit the PAT beam lines along the depth ρ and ϴ to estimate μeff (λ, ϴ) and then
use the known μs' to estimate  a (λ, 𝛳) within the US identified angular section of the ovary.  a
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(λ, 𝛳) is used as an initial guess of μa (λ,ρ,ϴ) to estimate initial guess of 𝐶̂ (𝜌, 𝛳). From the
estimated initial 𝐶̂ (𝜌, 𝛳), we iteratively reconstruct 𝐶̂ (𝜌, 𝛳) and  a (λ,ρ,ϴ). With these two initial
estimates of  a (λ, 𝛳)and 𝐶̂ (𝜌, 𝛳), the optimization converges.
However, this method requires that the tissue 𝜇 ′ 𝑠 value is known and its change from background
is small. From our initial experience on blood tube phantoms, the reconstructed μa(λ,ρ,ϴ) is not
very sensitive to 𝜇 ′ 𝑠 , thus one wavelength measurement of 𝜇 ′ 𝑠 should offer a good estimation.

5.3 Results
We have demonstrated this approach in blood tube experiments. The optical absorptions of the
five tested blood tubes at different wavelengths are shown in Figure 5.3. By comparing the plots
in this figure to the molar extinction coefficient of oxy and deoxy hemoglobin shown in Figure
5.4, it is clear that the absorption coefficient spectrum follows the molar extinction coefficient
spectrum of deoxyhemoglobin for lower sO2 percentages and it becomes closer to the spectrum of
oxyhemoglobin when the sO2 percentage increases.
Figure 5.5 shows a scatter plot of quantitative HbTs in uM (a) and a scatter plot of the calculated
sO2 values (b) calculated from μa (λ,ρ,ϴ) obtained from depths of 1 cm to 4 cm for each of five
sets of blood tube experiments described before. The calibrated HbT shown in black circle was
measured from a Microplate Spectrometer (BIoTek) at Dr. Doctor’s lab and a whole blood
μ's=10cm-1 was used as an estimate for computing  a (λ, 𝛳). As shown in Figure 5.5 a, HbT is
quite accurate for the sO2 values in the middle but has slight larger errors at the two ends of the
sO2 values of 24.9% and 97.6%. This is related to the relatively lower laser power at 730nm and
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830 nm of our system, and we will improve the system by replacing the pump laser which is quite
old.

Figure 5.3: The calculated optical absorption for blood samples with different oxygen
concentrations.

Figure 5.4: the molar extinction coefficient of oxy and deoxyhemoglobin.
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a

b

Figure 5.5: a: The calculated vs the actual total hemoglobin values of the tested blood samples. b:
The calculated vs the actual oxygen saturation percentages of the tested blood samples.

About the sO2 scatter plot (Figure 5.5 b), the standard deviations (STD) for each calculated sO2
at all depths were 10.8%, 3.8%, 4.1%, 6.9% and 6.5%, respectively with mean STD 6.4%. The
sO2 curve from PAT data showed a typical bell shape, which slightly reduces the calculated sO2
dynamitic range by providing a higher sO2 estimate at extremely low blood sO2 levels and a lower
sO2 estimate at extremely high sO2 levels. However, this dynamic range reduction affects the
calculated sO2 of both malignant and benign/normal ovarian tissues equally, they are all
distributed in a similar depth range of different sO2 values. To sum up, based on the results in
Figure 5.5, the mean error of the estimated HbT values for blood tubes at all depths with respect
to the real values are less than 13%. Furthermore, the largest sO2 estimation error is 7.5% for the
blood sample with sO2 of 24. 9%
In the future, using tissue phantoms, like the one introduced in [20], we will validate this approach
for sensitivity to μ's, sensitivity to the initial estimate of  a (λ, 𝛳)and 𝐶̂ (𝜌, 𝛳), sensitivity to lower
HbT concentrations, and robustness of the approach to different types of ovarian tissue (solid vs.
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cystic). More ex-vivo measurements of average ovarian tissue μa and μ's will be made at 730nm,
780nm, 800 and 830nm using our DOT system [21]. The improvement in diagnostic accuracy for
malignant vs. benign/normal ovaries will be evaluated using our pilot PAT/US patient data.
Moreover, in the next step, we will try this method on our in-vivo ovarian data. In this case, as the
ovarian tissue, unlike intralipid solution, is not homogenous, 2-D model may not be a suitable
approximation for the problem and more complicated methods can be used to find the local fluence
in the tissue. If the above simple 2-D model is not robust to patient data, we will investigate the
full-field 3-D diffusion equation to iteratively compute the Ø(𝑟,  a , 𝜇 ′ 𝑠 ) distributions [19, 22].
Other computationally intensive inverse methods include non-linear iterative updating of the
absorption distribution [23], and optimization using model-based [24] and Monte Carlo based
approaches [25-27]. These methods have been demonstrated in simulations and phantom studies,
and their robustness in clinical applications will be evaluated.

5.4 Discussion and Summary
In this study, we conducted an experiment using blood tube phantoms to quantitatively evaluate the
absorption coefficient and functional features of different blood samples using PAT. The blood tube was
located at different depths in an intralipid solution, and PAT signals were acquired at each depth. As the
medium was homogenous, the optical fluence at each depth was simply calculated using Beer’s law. To
find the absorption coefficient of the blood, an optimization problem with two unknowns was solved using
conjugate gradient method. One of the unknown variables in this problem was the multiplication of system
response and Grüneisen parameter, and the other one was the absorption coefficient of the blood. Our
estimated absorption coefficient, HbT, and sO2 were close to the real values. In the future we will evaluate
the performance of this method on the data we have acquired from patients with ovarian masses.
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Chapter 6: Colorectal cancer diagnosis using
coregistered photoacoustic tomography and
ultrasound system
6.1 Introduction
Photoacoustic imaging (PAI) is an emerging technique which can provide high optical absorption
contrast images at reasonable microscale resolution and clinically relevant depths [1]. Several
studies have established that optical absorption parameters are important biomarkers directly
related to the tissue microvasculature, tumor angiogenesis or tumor hypoxia [2-4]. In general, PAI
is classified into photoacoustic microscopy (PAM) and photoacoustic tomography (PAT) [1].
Previously, PAM or Photoacoustic endoscopy (PAE) have demonstrated the capability of detecting
human colorectal cancer [5,6]. However, the low imaging speed (limited by the laser repetition
rate and scanning scheme), small imaging area, and shallow penetration depth (<7 mm) created
obstacles for clinical applications.
Compared with PAM, PAT is able to penetrate deeper with a faster data acquisition speed and a
larger field of view due to the use of ultrasonic arrays and a wide optical beam. Several studies
have demonstrated that PAT/US dual-modality imaging system can provide anatomical and
functional information in tumors [7-13], but no prior applications in the human distal GI tract have
been reported using PAT/US dual-modality imaging.

Adenocarcinoma of the colon and rectum is the second most common malignancy diagnosed
globally and the fourth leading cause of cancer mortality, with more than 100,000 new cases
diagnosed annually in the US [14-15]. Accurate staging and post-treatment surveillance of this
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prevalent disease are critical because treatment strategies are predicated upon the stage at
presentation and response to therapy – in some instances, detailed imaging allows certain patients
to avoid surgery altogether. While colonoscopy and biopsy are the gold-standard diagnostic tests
for colorectal cancers [16], multiple imaging modalities including optical imaging [17-18],
endoscopic ultrasound (EUS), pelvic magnetic resonance imaging (MRI), computed tomography
(CT) and positron emission tomography (PET) are also utilized.
Unfortunately, each of these modalities have critical weaknesses when evaluating colorectal
tumors. White light endoscopy (WLE) only detects macroscopic morphology and provides no
functional assessment of the imaged tissue. MRI has limited between-slice resolution and is often
unable to differentiate early tumors from benign neoplasia, committing patients to potentially more
invasive treatment regimens than needed [19,20]. Monitoring of tumors after chemotherapy and
radiation with MRI is often confounded by fibrotic reaction and edema, which can appear similar
to residual tumor [21]. CT has poorer resolution of the bowel wall layers in comparison to MRI,
subsequently limiting its ability to describe circumferential resection margin (CRM) status or
serosal invasion in locally advanced cases. Additionally, CT also cannot distinguish induration or
peritumoral fibrosis from frank malignant disease with a high degree of specificity, further limiting
its application in local tumor staging [19]. PET imaging is also plagued by poor resolution, and
EUS remains highly user-dependent and unable to resolve small islands of tumor [19]. Therefore,
critical need exists for precise imaging modalities of colorectal tumors for both staging and
therapeutic response evaluations.

In this study, we have imaged colorectal masses using a real-time co-registered PAT/US system
to delineate differences between benign and malignant tissue. To the best of our knowledge, this
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study is the first utilizing co-registered PAT/US to evaluate human colon samples. We investigated
the potential qualitative and quantitative capability of PAT functional and spectral parameters as
well as PAT/US images to identify malignant tissue.

6.2 Methods
6.2.1 Human Sample Preparation
Freshly resected colon and rectum samples obtained from patients undergoing surgery at
Washington University School of Medicine were imaged immediately after surgery. Patients with
known benign neoplasia (polyps) as well as malignancies (adenocarcinoma) were eligible for
imaging. Cancer patients who had received preoperative treatment with chemotherapy and /or
radiation were also included. The study was approved by the Institutional Review Board (IRB) at
Washington University (#201707066). Informed consent was obtained from all patients.
Specimens were obtained from the operating room as previously described 6.
A total of 20 tissue samples were imaged in the pilot study using the PAT/US system. This included
untreated colorectal adenocarcinomas (n=10), precancerous polyps (n=5), colorectal cancer
following chemotherapy or radiation and chemotherapy (n=4), and post polypectomy (n=1). Two
treated patients have achieved complete pathological response and two partial response. The
majority of patients underwent hemicolectomy for cancer and were found to have malignancy on
histologic analysis (Table 6.1).
Table 6.1: Summary of Specimens
Patient
ID
1
2
3

Surgery
Total colectomy
Right Hemicolectomy
Right Hemicolectomy

Pathology
Moderately differentiated adenocarcinoma (T3)
Tubular adenoma (precancerous polyp)
Moderately differentiated adenocarcinoma (T2)
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4

Sigmoid colectomy

5
6

Right Hemicolectomy
Low anterior resection

7
8

Left colectomy
Low anterior resection

9
10
11
12
13
14
15
16

Low anterior resection
Right hemicolectomy
Right hemicolectomy
Right hemicolectomy
Right hemicolectomy
Left colectomy
Left Hemicolectomy
Low anterior resection

17
18
19

Sigmoidectomy
Transverse colectomy
Low anterior resection

20
21

Low anterior resection
Total colectomy

22
23

Right hemicolectomy
Right hemicolectomy

Treated moderately differentiated adenocarcinoma
(T3); post chemotherapy
Tubular adenoma (precancerous polyp)
Complete pathologic response-no residual tumor
after radiation and chemotherapy
Moderately differentiated adenocarcinoma (T2)
Complete pathologic response-no residual tumor
following radiation and chemotherapy
Tubulovillous adenoma (precancerous polyp)
Moderately differentiated adenocarcinoma (T3)
Moderately differentiated adenocarcinoma (T2)
Moderately differentiated adenocarcinoma (T4)
Tubular adenoma (precancerous polyp)
Moderately differentiated adenocarcinoma (T4)
Tubulovillous adenoma (precancerous polyp)
No residual tumor following prior polypectomy*
Moderately differentiated adenocarcinoma (T3)
Moderately differentiated adenocarcinoma (T2)
Treated moderately differentiated adenocarcinoma
(T3); post radiation and chemotherapy
Moderately differentiated adenocarcinoma (T3)
Moderately to poorly differentiated adenocarcinoma
(T3)
Moderately differentiated adenocarcinoma (T3)
Differentiated adenocarcinoma (mixed polyp and
adenocarcinoma)

Note: T is the primary tumor depth of invasion, per TNM guidelines.
* No residual tumor was found after polypectomy. We have grouped this case with the complete
responders.

6.2.2 Extraction of Functional, Spectral, and Textural features
Several functional, spectral, and textural features were extracted from the PAT and US data and
images as given in Table 6.2. These features were calculated as given in previous chapters in this
dissertation. Examples of spectral feature calculation for a malignant and a benign colon sample
are given in Figure 6.1.
Table 6.2: Abbreviations
Abbreviation
rHbT

Description
relative total hemoglobin
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SS (PAT)
0.5MHz SI (PAT)
MBF (PAT)
SS (US)
0.5MHz SI (US)
MBF (US)
Sig_rad
Homogeneity
Energy
Contrast
Correlation

mean PAT spectral slope
0.5 MHz spectral intercept from PAT spectra
mid-band fit from PAT spectra
mean US spectral slope
0.5 MHz spectral intercept from US spectra
mid-band fit from US spectra
standard deviation of the mean radon transform
the homogeneity of image textures
the grayscale distribution homogeneity of images and
texture crudeness
the sharpness of images and the depth of texture
grooves
the consistency of image texture

Figure 6.1: Top row: co-registered rHbT and US images of a cancerous (left) and a normal
(right) colon sample. Bottom row: the calibrated PAT power spectra along with their fitted lines
in the regions marked with the angular dashed lines in each image.
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6.2.3 Feature Selection and Classification
A two-step approach was used to select features most likely to differentiate normal from untreated
malignant tissue. In the first step, all previously discussed PAT/US features were tested in
univariate analysis between untreated cancer and normal regions, and p values were generated by
two-sample two-sided Student’s t tests. The features where p > 0.05 – which we concluded a priori
not to be significantly associated with malignancy – were excluded from the classification model
(Table 6.3).
Table 6.3: Significance testing of individual covariates as related to tissue diagnosis
Feature
rHbT
SS (PAT)
0.5 MHz SI (PAT)
0.5 MHz SI (US)
Homogeneity
Energy
Sig_rad
MBF (PAT)
MBF (US)
SS (US)

p-value
<0.001
<0.001
0.002
0.01
0.01
0.02
0.03
0.12
0.23
0.55

Next, logistic a general logistic mode (GLM) and a support vector machine (SVM) were used to
evaluate the strength of association of each feature with the ultimate tissue diagnosis, and a
prediction model was then constructed with significant covariates. In total, 18 areas selected from
18 specimens and 12 malignant areas from 12 untreated cancer specimens were used to construct
and evaluate the prediction models. Out of these, 12 normal and 8 malignant areas were used for
prediction model derivation and the rest (6 normal and 4 malignant areas) for internal model
validation. The receiver operating curve (ROC) and the area under the curve (AUC) were used to
evaluate the accuracy of the model. Finally, a second prediction model was constructed without
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rHbT to determine how limiting the PAT/US device to a single wavelength would affect
identification of malignancies.

6.3 Results
6.3.1 Qualitative Analysis: Baseline Characteristics of US and PAT Images
Colorectal tissues are composed primarily of fluid, lipid, collagen, and muscle. The general
architecture (from superficial to deep) in a normal specimen is mucosa (fluid-filled cells
surrounded by lipid bilayers), submucosa (largely composed of extracellular collagen matrix and
some muscle fibers), muscularis propria (muscle), and adipose tissue (lipid). In malignancy, the
individual cell types are similar but the architecture is distorted because cancerous cells of mucosal
origin penetrate into the deeper layers of the organ. As these cells invade, the organized structure
of the tissue is lost.
Figure 6.2 shows specimen photographs, US images, and co-registered PAT/US rHbT maps as
well as histologic images from a representative region of normal colon samples (6.4 a - 6.4 d), and
a colorectal malignancy (6.4 e - 6.4 h). The white arrows indicate the scanning direction along
which B-scans were recorded at four different wavelengths (the imaging plane is perpendicular to
the scanning direction). In the standalone ultrasound images, the normal layered structure of the
colorectal wall is clearly delineated (6.4 b). In the presence of malignancy, however, this organized
structure is distorted by the tumor and loses the clear delineation of mucosal, submucosal, and
muscular layers. These findings mirror the differences in histology among the specimens; in
contrast to the ordered layering of the normal colonic wall (images 6.4 d), the tumors appear
disorganized with destruction of the underlying colonic architecture (images 6.4 h).
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Additionally, the rHbT maps computed from coregistered PAT/US images of benign regions show
significantly lower rHbT signals (6.4 c) than maps from the malignant lesions (6.4 g). As
demonstrated in these representative images, normal tissue was found to have almost no detectable
rHbT signal. In contrast, malignant tissue showed much higher concentrations of hemoglobin
around the tumor bed. Again, these findings appear corroborated by histologic examination. In
comparison to the relative paucity of large blood vessels in normal tissue, the malignancies were
more vascular and contained large blood vessels (red arrows in images 6.4 h).
It is interesting to note that fatty tissues have limited PAT signals in the outer portions of the
specimens. This is not surprising since we are specifically targeting hemoglobin – which is not
concentrated in fatty tissue – as our chromophore of interest, and therefore we image within the
730-830 nm wavelength range. Additionally, all PAT images are displayed with the same dynamic
range of -10 dB, so anything below this level is not displayed. The fatty tissue, due to its lack of
vascular structures, falls below this range.
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Figure 6.2: Color photograph, US image, rHbT map, and H&E image from representative areas
of (a)-(d) a normal region and (e)-(h) a malignant region of pretreatment colorectal cancer tissue.
Red arrows identify blood vessels within the histologic images.

Figure 6.3: Color photograph, US image, rHbT map, and H&E image from representative areas
of (a)-(d), a pretreatment colorectal cancer, (e)-(h) a post-treatment colorectal cancer tissue with
residual disease, and (i)-(l) a post-treatment colorectal cancer tissue without residual disease.

6.3.2 Evaluation of Treated Tumors
Figure 6.3 shows corresponding images from a representative untreated colon cancer sample (6.5
a - 6.5 d), a colon tumor treated with preoperative chemotherapy (6.5 e – 6.5 h), and a rectal
malignancy that received radiation and chemotherapy prior to surgical resection (6.5 i - 6.5 l). The
untreated tumor displays findings consistent with other untreated colorectal cancers: loss of
layered wall structure, increase in rHbT signal, and increased vascularity throughout the tumor
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bed. However, treatment appears to reverse these changes. For example, the PAT signal appears
to diminish with chemotherapy (6.5 g) and even disappear altogether with complete destruction of
the tumor (6.5 k). Additionally, ultrasound imaging demonstrates a return to the normal wall
structure with complete tumor destruction (6.5 j). Histologic comparison among specimens also
correlates with these findings; a reduction in vasculature along with return to a semi-organized
mucosal structure is noted throughout the treated specimens.

6.3.3 Quantitative Analysis
In addition to the above qualitative comparisons, we extracted features from 23 non-overlapping
areas obtained from 12 untreated malignant tumors, 6 polyps, 3 post-treatment complete
responders or patients with no residual tumor following prior polypectomy, and 2 post-treatment
non-responders. We also extracted features from 18 normal non-overlapping areas from specimens
of normal regions. Thus, a total of 41 non-overlapping regions were used. Note that each nonoverlapping area was obtained from each separate sample. These regions were identified by the
attending pathologist.
Figure 6.4 (a-g) shows the boxplots of the seven features calculated from the functional, spectral
and image differences between the different types of colorectal tissue. The n number given in the
plots corresponds to the total number of areas. The malignant regions demonstrated elevated
rHbT, 0.5MHz SI (PAT) and 0.5MHz SI (US) score smaller (less negative) compared to normal
and precancerous regions. For SS (PAT), the malignant regions score below normal and
precancerous polyps. Treated tumors with complete response were found to have similar scores to
normal tissue, while treated regions with residual cancer have scores similar to untreated cancers.
Due to the limited number of treated cancers, statistics were not performed for these two treated
categories.
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Figure 6.4: Boxplots of (a) total hemoglobin; (b) the mean spectral slope from PAT spectra; (c)
0.5 MHz spectral intercept from PAT spectra; (d) 0.5 MHz spectral intercept from US spectra;
(e) energy from the second order statistics of PAT images; (f) homogeneity from the second
order statistics of PAT images; (g) standard deviation of the mean radon transform.
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To distinguish untreated malignant from normal colon tissues, GLM and SVM classifiers were
established. These classifiers were developed using the independent features with a p-value less
than 0.05 between malignant and normal colon tissues. To determine if two features are
independent, Spearman’s correlation was calculated between each pair of features (Table 6.4). To
train each classifier, we first used the feature with the lowest p-value and then added other features
to the feature set one by one. We continued to include features to the feature set until no increase
in the AUC value for the testing data set was observed. We found that when rHbT was included in
the feature set, the best performance of both the GLM and SVM classifiers (the highest AUC value
for the testing data set) was achieved when rHbT and 0.5MHz SI (PAT) were employed to train
the classifier, although SS (PAT) has a lower p-value than 0.5MHz SI (PAT). Adding other
features did not improve the AUC for the testing data set.
Table 6.4: The correlation between significant features used in this study

rHbT
SS (PAT)

SS (PAT)

0.5MHz SI
(PAT)

0.5MHz
SI (US)

Homogeneity

Energy

Sig_rad

0.65

0.45

0.27

0.34

0.41

0.37

0.67

0.23

0.42

0.46

0.29

0.21

0.49

0.41

0.4

0.41

0.37

0.31

0.79

0.91

0.5MHz SI (PAT)
0.5MHz SI (US)
Homogeneity
Energy

0.82

Figure 6.5 shows the ROC curves and AUC values of the training (left) and testing (right) data sets
using GLM (top row) and SVM (bottom row) classifiers. As shown in this figure, when the features
set include just rHbT, the AUC values for the training and testing data sets are 0.95 and 0.93 for
both classifiers, respectively. Adding 0.5MHz SI (PAT) to the features set results in a significant
improvement in the AUC values for both the training and testing data sets (0.97 and 0.95 for the
training and testing data sets for both classifiers, respectively). The three image features (Sig_rad,
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Homogeneity, and Energy) did not improve the AUC values for either the training or testing data
sets.

Figure 6.5: ROC curves and their associated AUC values for the training and testing data sets in
the presence of rHbT in the feature set. (a), (b) GLM classifier performance. (c), (d) SVM
classifier performance.
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Figure 6.6: ROC curves and their associated AUC values for the training and testing data sets in
the absence of rHbT in the feature set. (a), (b) GLM classifier performance. (c), (d) SVM
classifier performance.

Finally, the performance of the GLM (top row) and SVM (bottom row) classifiers without rHbT
(the single-wavelength model) are presented in Figure 6.6. Note that although the difference
between some of the PAT image features in malignant and normal samples is statistically
significant, none of these features improve the AUC for the testing data sets. The best performance
of GLM classifier is achieved when the only spectral feature SS(PAT) is included in the feature
set. The best performance of SVM classifier is achieved when the spectral features SS(PAT),
0.5MHz SI(PAT), and 0.5 MHz SI(US) are included in the feature set. The testing AUC in this
case is 0.89 for the GLM classifier and 0.91 for the SVM classifier.

6.4 Discussion and Summary
In this pilot study of co-registered ultrasound and photoacoustic tomography, we found significant
qualitative and quantitative differences between malignant tumors and normal tissue within human
colorectal specimens. Specifically, the parameters rHbT, 0.5MHz SI (PAT), 0.5MHz SI (US), and
SS (PAT) differ between the two tissue types imaged, suggesting that PAT may be able to
differentiate malignant from normal tissue in the colon and rectum. Combined with the PAT
system’s tissue penetration depth of over 4 to 5 cm (depending on the background tissue optical
properties), these findings suggest that PAT may be able to augment extant radiographic
technology in the diagnosis, management, and surveillance of colorectal cancer.
As demonstrated by Guan et al [22] and Ronald [23], PAT spectral features are related to the size
and concentration of the optical absorbers. The slope decreases (more negative) as PA absorber
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sizes increase and the intercept increases (less negative) as the sizes and concentrations of the
absorbers increase. We believe that malignant lesions have larger absorber sizes and higher
concentrations compared with normal colorectal tissues due to their increased microvessel
networks. As introduced by Lizzi and co-workers [24], US spectral slope depends on acoustic
scatter size while spectral intercept depends on scatter sizes, concentrations and acoustic
impedances of tissue scatter matrix. These parameters have been found valuable to characterize
liver, eye [24], prostate [25], and breast lesions [26]. We believe that the distorted tissue
architecture and abundance of cancerous cells are the source of the US spectral contrast between
malignant and normal colorectal tissues. However, the findings of the PAT and US spectral
features of colorectal diseases may or may not be applicable to diseases of other organs.
Several technical limitations must be considered with our data. First, we imaged colorectal
specimens obtained from routine surgeries and these tissues were typically with large pathologic
components that often appeared malignant by visual inspection after specimens were open. These
lesions may or may not need advanced PAT and US features for diagnosis. However, these lesions
are excellent examples for identifying PAT and US feature characteristics that differ between
cancerous and normal tissue. With this information known, we can target less obvious lesions as
we look to test the utility of the device in identifying cancer margins and residual tumors after
chemo-radiation treatment in patient.
The second limitation of this study is the low image resolution of our prototype. The image
resolution is only ~250 μm due to the commercial endo-cavity ultrasound transducer array (6 MHz
central frequency, 80% bandwidth). Because this resolution will impact future clinical applications
of the device, we plan to upgrade the ultrasound system with a transducer array of more than 15
MHz to address this problem in future studies. Third, sO2 was not calculated in this study since
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all specimens were imaged after resection, resulting in significantly altered sO2 compared to
normal living tissue. sO2 is a significant biomarker for characterization of cancer [11] and
assessment of treatment response.
Thirdly, the limited sample size could lead to overfitting of the classifiers if enough care is not
taken to develop the classifiers. As a rule of thumb, overfitting is least possible to occur if the
number of samples is 10 times or higher than the number of independent predictors [27]. Based on
this rule, as we have a total of 30 samples (18 normal colorectal tissues and 12 untreated malignant
colorectal tissues) for ROC analysis, the maximum number of the predictors that should be used
to avoid overfitting would be three. Figure 6.5 shows that when rHbT is present in the feature set,
the best performances of both GLM and SVM are achieved when rHbT and 0.5MHz SI (PAT) are
the only features used to train the classifiers. Adding SS (PAT) to these feature set neither changes
the value of the AUC for training data sets, nor increases the AUC for the testing data set.
Moreover, when rHbT is not included in the feature set, employing the combination of SS (PAT),
0.5MHz SI (PAT), and 0.5MHz SI (US) features for developing the classifiers would result in the
best performance of SVM classifier and SS (PAT) only would result in the best performance of
GLM classifier (Figure 6.6). While adding Sig_rad increases the AUC value for the training data
set, it decreases the AUC values for the testing data set in both classifiers. This would mean that
our classifiers have most probably been overfitted when four features have been used. In this study,
to further protect our classifiers from overfitting, repeated rounds (100 times) of cross validation
were applied by randomly selecting 2/3 of the samples for training and 1/3 of the samples for
testing. The average ROC and AUC values were reported as the results.
In summary, a real-time co-registered PAT/US system was used to image and characterize
colorectal masses ex-vivo in this pilot study. 23 colon and rectum samples (19 colon and 4 rectum)
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were imaged, rHbT was computed from 4 wavelength data, and seven quantitative features were
extracted from PAT and US power spectra and images. In pre-treated malignant colorectal tumors,
we found the cross-section structure to be highly disorganized with a significantly higher rHbT
concentration compared to normal and precancerous regions. We performed classifications on the
malignant and normal colon regions using GLM and SVM classifiers both with and without HbT
in the feature set. When rHbT was employed to construct the classifiers with 0.5 MHz SI (PAT),
GLM and SVM classifiers achieved optimal AUC values for the training and testing data sets (0.97
and 0.95, respectively). The small number of treated tumors included in this dataset limits the
statistical power of the analysis, but the functional, spectral and image parameters do appear more
similar to normal colorectal tissue in tumors that have experienced complete responses compared
to partial responders. These results indicate potential of using PAT/US for future cancer screening
and post-treatment surveillance of the colon and rectum. Moving forward, we plan to increase the
resolution of our system by using a high frequency US array and then adapt the technology to an
endo-rectal probe, which will allow us to test the functional and spectral feature differences in invivo human tissue.
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Chapter 7: Colorectal cancer diagnosis using
coregistered photoacoustic microscopy and
ultrasound system – comparison of CNN and
GLM classifiers
7.1 Introduction
Colorectal cancer is the third most common cancer diagnosed in both men and women in the
United States [1]. While treatment often involves chemotherapy, radiation, and surgical resection,
recent advances in neoadjuvant (preoperative) treatment of locally advanced rectal cancers
(LARC) have enabled 20-30% of patients to safely avoid surgery altogether [2-5]. However, this
“watch and wait” depends on accurate assessments of tumor regression and high-resolution and
high-sensitivity surveillance imaging for tumor recurrence.
Standard surveillance modalities include physical exam, endoscopy with biopsy, and MRI;
however, each of these modalities have distinct weaknesses in the post-treatment setting. [6-12].
The poor performance of current technology makes it extremely difficult to identify patients who
can safely avoid surgery (pCRs) from those who need resection (non-responders).
To overcome these challenges, we developed a co-registered endorectal photoacoustic microscopy
and ultrasound (PAM/US) system to assess rectal cancer treatment response [13-14].
Photoacoustic imaging (PAI) is a hybrid imaging technology that uses a short laser pulses to excite
hemoglobin molecules endogenous to the human body. The resulting acoustic waves are then
acquired by US transducers and analyzed for vascular bed quantification. This process has been
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utilized in many different areas such as breast cancer [17-18], lung cancer [19-20], ovarian cancer
[21], skin cancer [22], and colorectal cancer [13-14].
A convolutional neural network (CNN) is an artificial intelligence algorithm with remarkable
capabilities for automated image analysis [23]. To quantitatively interpret the large volumes of
data acquired by the PAM/US system, we designed and incorporated deep-learning CNN models
in the PAM system (PAM-CNN) [14]. While our deep-learning PAM-CNN model can accurately
assess rectal cancer treatment response, it requires a large training and validation data set. The
key question remains if the PAM-CNN outperforms traditional histogram-feature based models.
In this study, using 24 ex-vivo and 10 in-vivo data sets, we compare the performances of the PAMCNN and the traditional histogram-parameter-based classifiers in rectal cancer treatment
evaluation. Unlike CNN models, a generalized logistic regression (GLM) classifier does not
require a large dataset for training and validation, however, imaging features must be extracted
and evaluated on their diagnostic accuracy. We have computed five PAM image histogram
features and used them to train, validate and test GLM classifiers. The performance of deep
learning based CNN models is compared with GLM classifiers. To the best of our knowledge,
this study is the first to establish the role of deep-learning PAM-CNN in rectal cancer evaluation.

7.2 Methods
7.2.1 Patients, specimens, and PAM imaging
Briefly, 10 participants (mean age, 58 years; range 42 – 68 years; 2 women and 8 men) completed
radiation and chemotherapy from September 2019 to September 2020 and were imaged with the
PAM/US system prior to surgery. Colorectal specimens from another group of 24 patients who
had undergone surgery were studied ex-vivo. All studies were approved by the institutional review
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board of the Washington University School of Medicine, and all patients provided written
informed consent. In the ex-vivo study, each specimen was evaluated within one hour of surgical
resection and prior to formalin fixation. In the in-vivo study, patients who had previously
undergone preoperative treatment with radiation and chemotherapy were imaged in-vivo before
resection.

7.2.2 PAM/US endoscope
The PAM endoscope consists three parts: a handle, a water channel (the main body), and an
imaging head, as shown in Figure 7.1 A [14]. Briefly, the water inlet which allows water injected
from a syringe to inflate a water balloon covering the image head for ultrasound coupling. A
stepper motor in the handle turns a hollow shaft in the water channel to rotate the image head 360°
for full circle imaging. An optical fiber inside the hollow shaft delivers laser pulses to the imaging
head. An ultrasonic transducer (20 MHz, 75% bandwidth) fixed on the imaging head both
transmits and receives ultrasound signals, and also receives PA signals. An Nd: YAG laser
working at 1064 nm with a 1000 Hz pulse repetition rate is the light source. A 0.15 cm2 tissue area
is illuminated by 3.6 mJ laser pulses from the probe tip, resulting in a surface optical fluence of 24
mJ/cm2, which is well within the ANSI safety threshold (100 mJ/cm2) at 1064 nm [24]. This
fluence is further reduced by energy diffusion caused by the balloon.
During imaging, the PAM endoscope is inserted transanally through a proctoscope, (Figure 7.1
C). Ruled scales on the water channel (Figure 7.1 B) show how deeply the endoscope is inserted
into the rectum where the images are obtained.
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Figure 7.1: PAM endoscope (A), scales on water channel (B) and endoscope in a proctoscope,
with a balloon on the tip (C).

7.2.3 PAM and US data selection for training/validation and testing of models
For training and validation, three to five regions of interest (ROIs) were selected at uniformly
spaced locations on each PAM or US B-scan image acquired from normal regions or a tumor bed
(Figure 7.2). For example, the red ring in Figure 7.2 represents mucosa vasculature, which is
continuous in the normal image of Figure 7.2 B. The blue rectangles indicating ROIs are uniformly
spaced along the perimeter of the image. In the cancer image, the dark zones and discontinuities
in the red ring from approximately 9:00 to 1:00 o’clock indicate tumor, so the ROIs are uniformly
spaced in that segment. A total of 2600 US ROIs (1262 normal and 1496 cancerous) and 2004 PA
ROIs (1207 normal and 797 cancerous) were compiled from 24 patients’ ex-vivo images and 10
patients’ in-vivo images. Two ex-vivo samples showed a low signal-to-noise ratio (SNR) on PAM
images due to a laser energy problem. We excluded those two samples in training PAM-CNN and
PAM-GLM models. For the US-CNN and US-GLM models, we used all 24 ex-vivo and all 10 invivo patient data.
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Figure 7.2: Example co-registered PAM and US images showing ROIs of (A) residual cancer
tissue, area in green dashed line boxes, and (B) normal tissue, area in blue boxes. PAM ROIs are
cropped from PAM images, and US ROIs are cropped from US images.

We divided the total of 2004 PA ROIs and total of 2600 US ROIs into two discrete data sets – one
for model training and validation and another for testing, respectively. The training set included
all ex-vivo cases (including normal, pCR responders, and cancers) and half of the in-vivo patient
data consists of normal regions, including the normal area and pCR treated tumor bed, and 3 cancer
beds from non-responders. Of the training set ROIs, 80% were used for training with the remainder
for internal validation. The testing set contained the other half of the in-vivo patient data consisting
of 5 normal regions, one tumor bed of a pCR, and 3 cancer samples from non-responders.

7.2.4 GLM models
We used selected image features of ROIs to develop PAM-GLM and US-GLM models. To
calculate the histogram of each ROI, we divided the ROI into 32 bins. The bar height of each bin
was then computed by dividing the number of pixels with a given value in an associated range by
the size of the image. From the histogram of each ROI, we then extracted five features: mean,
standard deviation, skewness, kurtosis, and energy.
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All the PAM and US features showed significant differences between malignant and normal
colorectal tissues (p<0.05) (Appendix Figure 7.1S and Figure 7.2S). Therefore, all these features
were considered as potential candidates when building PAM-GLM and US-GLM models. To
prevent model overfitting, the Spearman’s correlation coefficient between each of the histogram
features were calculated (Appendix, Table 7.1S). We developed PAM-GLM classifiers using each
histogram feature separately, as well as using combinations of features with low correlation values.
The mean AUCs of the training/validation and testing data sets as well as their 95% confidence of
interval were computed for each classifier. The same process was followed to construct US-GLM
classifiers.
To remove bias in selecting in-vivo data for training and validation, we trained the classifiers 10
times. The training/validation and testing data sets are the same as those used for CNN models
described in next section.
Figure 7.3 (PAM-GLM) and Figure 7.4 (US-GLM) show examples of the first order statistical
features calculated from malignant rectal tissue ROIs (shown in Figure 7.2 A) and normal rectal
tissue ROIs (shown in Figure 7.2 B). As shown in Figure 7.3, in PAM ROIs, the malignant tissue
has a lower mean and standard deviation, while the other three features are higher. In Figure 7.4,
malignant US ROIs show a lower mean and standard deviation than that of the normal US ROIs.
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Figure 7.3: First order statistical features calculated from malignant rectal tissue PAM
ROIs (A) and normal rectal tissue PAM ROIs (B)

Figure 7.4: First order statistical features calculated from malignant rectal tissue US ROIs (A)
and normal rectal tissue US ROIS.

Figures 7.1S in Appendix show the boxplots of the histogram features of the PAM ROIs. The pvalue for each feature, calculated from a two-sided statistical t-test, is indicated on each plot. All
features are statistically significant (p<0.05), however, they are not equally important. To assess
the importance of each feature, we first fit a regression model to each feature separately, using all
the available data (ex-vivo and in-vivo patients), and then we found the AUC of the fitted model.
As shown in Table 7.1, Std, Mean, and Kurtosis respectively provide the highest AUC values
among all the features of PAM images. While Std and Mean are highly correlated, the correlation
value between Mean and Kurtosis is less than 0.5 (Table 7.S1). Therefore, these two features are
used together to develop PAM-GLM classifiers.
Similarly, boxplots of the five features from US ROIs are given Figure 7.2S, and the AUC feature
values of the fitted model are shown in Table 7.1. Based on this table, Std, Energy, and Mean are
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respectively the most important features of the US images. However, they all are highly correlated
with each other (Table 7.S2).

Table 7.1: AUCs of the fitted regression model developed using features of PAM and US
images.
Feature

AUC (PAM)

AUC (US)

Mean

0.76

0.81

Std

0.79

0.86

Skewness

0.71

0.57

Kurtosis

0.73

0.62

Energy

0.70

0.85

7.2.5 CNN models
The PAM-CNN (or US-CNN) architecture contained two sequential feature extraction layers and
two fully connected layers [14]. Briefly, each extraction layer had a convolutional layer followed
by a pooling layer. To optimize the validation results, the convolution kernel and max-pooling
kernel sizes were set to 3 × 3 and 4 × 4, respectively. The first fully connected layer was a 512node hidden layer, and the second fully connected layer (output layer) generated two output
classifications – normal or cancerous. “Normal” described a layer-like vascular distribution in a
PAM image or a layer structure in a US image, and “cancerous” described an absence of the normal
vasculature pattern in PAM images, or an absence of the layer structure in US images. A softmax
activation function in the output layer generated the probabilities of each of the two possible
classifications (cancer or normal) for an input image; for each input ROI of a PAM or US image,
the CNN model outputted the probability of a normal classification compared to the threshold (e.g.
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>50% is normal). In all the other layers, a “ReLU” activation function immediately set all negative
values to 0 and left positive values unchanged, avoiding exploding or vanishing gradient problems.
To avoid biased selection, we trained and validated 10 PAM-CNN and US-CNN models each
using all the ex-vivo data and a randomly selected half of the in-vivo patient data, while reserving
the other half for testing. The maximum number of epochs was 20, with early stopping (a tolerance
of 2 epochs) monitored by validation accuracy. If there was no increase in validation for two
successive epochs, training was stopped. Stochastic gradient descent was used with a batch size of
20, and the RMSprop optimizer function was used to optimize the neural net weights. The learning
rate was set to 10-3 with a decay of 10-5. In each model, 80% of the ROIs from the training &
validation set were used to train the model, the remaining 20% were used for validation, and 20×
cross validation was performed.
The ROIs of each in-vivo normal or tumor bed patient images were either all used in training or
all used in testing. Each of the 10 CNN models was tested on a randomly selected half of the invivo data and generated an ROC. The overall performance of the classifier was measured by the
mean AUC of the 10 models.
The method for calculating PAM-CNN’s AUC is different from that of our previous report [14],
which leads to a slightly different AUC value. In previous work, the training and validation data
set was fixed, which was consisted of 24 ex-vivo and five in-vivo data set. The PAM-CNN’s AUC
obtained from another five in-vivo data set unseen by PAM-CNN for testing is 0.98. In this study,
we have done a more thorough investigation. The ex-vivo data set is still fixed for training and
validation, but the five in vivo data set for training and validation and the five in-vivo data set for
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testing were interchanged randomly for 10 times, and the 10 AUC was used to generate the mean
value of AUC.

7.3 Results
7.3.1 GLM models
Table 7.2 shows the mean AUCs and 95% confident of interval for PAM-GLM classifiers
developed using single features, as well as feature pairs that are weakly correlated (based on Table
S1). As can be seen, the "Mean-Kurtosis" combination results in a better testing performance than
"Mean" alone, and a better training performance than "Kurtosis" alone. In the case of US-GLM
(Table 7.3), the classifier which is built using “Std” alone performs best on both training and testing
data sets (mean AUCs of 0.86 and 0.66 for training and testing data sets, respectively).
Table 7.2: Training and testing mean AUC values for PAM-GLM classifiers developed using
different combinations of weakly correlated features. The 95% confidence of interval values are
also shown in front of each mean AUC value.
Feature
combinations

Training AUC

Testing AUC

(95% CI)

(95% CI)

Mean

0.77 (0.767-0.777)

0.80 (0.793-0.807)

Std

0.79 (0.788-0.793)

0.76 (0.746-0.770)

Skewness

0.71 (0.708-0.719)

0.82 (0.815-0.825)

Kurtosis

0.73 (0.724-0.734)

0.82 (0.817-0.827)

Energy

0.72 (0.712-0.727)

0.74 (0.724-0.758)

Mean, Kurtosis

0.74 (0.732-0.743)

0.82 (0.808-0.820)

Std, Energy

0.80 (0.799-0.807)

0.76 (0.750-0.773)

Kurtosis, Energy

0.75 (0.744-0.750)

0.81 (0.805-0.817)
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Table 7.3: Training and testing AUC values for US-GLM classifiers developed using different
combinations of weakly correlated features. The 95% confidence of interval values are also
shown in front of each mean AUC value.
Feature
combinations

Training AUC

Testing AUC

(95% CI)

(95% CI)

Mean

0.82 (0.818-0.820)

0.64 (0.629-0.657)

std

0.86 (0.860-0.862)

0.66 (0.650-0.674)

skewness

0.59 (0.587-0.591)

0.42 (0.405-0.443)

Kurtosis

0.64 (0.635-0.639)

0.34 (0.326-0.344)

energy

0.85 (0.851-0.854)

0.61 (0.600-0.621)

Mean, kurtosis

0.82 (0.819-0.822)

0.60 (0.581-0.618)

Std, skew

0.86 (0.860-0.862)

0.65 (0.643-0.664)

Std, kurtosis

0.86 (0.858-0.860)

0.65 (0.642-0.666)

Kurtosis, energy

0.86 (0.856-0.858)

0.63 (0.617-0.638)

Figure 7.5 (A) and (B) respectively show the mean training and testing ROCs of three of the best
performing (based on both training and testing AUCs) classifiers developed using PAM histogram
features. As shown in these plots, “Kurtosis” alone results in a slightly better performance on the
testing data set than the other feature combinations (see the 95% CI values in the table). It is worth
noting that although adding “Mean” to the features set negligibly lowers the AUC of the testing
data set, it increases the AUC of the training data set by 0.01. Finally, the reason for the slightly
poor training performance than testing for different combinations of features is that the training
data set includes both in-vivo and ex-vivo ROIs while the testing data set contains only in-vivo
ROIs. Overall, our in-vivo data have demonstrated slightly better classification between malignant
and normal colorectal tissue than the ex-vivo data.
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Figure 7.5: The average ROC of the training (A) and testing (B) data sets for different
combinations of features set. The features were extracted from PAM images. The 95% CIs are
indicated in parentheses.

In the case of US-GLM, using the “Std” histogram feature demonstrates the best prediction AUC
of 0.68, as seen in Figure 7.6 (B). Adding any other uncorrelated features does not improve the
AUCs of the training or testing data sets as shown in Figure 7.6 (A) and (B).
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Figure 7.6: The average ROC of the training (A) and testing (B) data sets for different
combinations of features set. The features were extracted from US images. The 95% CIs are
indicated in parentheses.

7.3.2 CNN models
The mean ROC and AUC of the CNN models were computed from 10 CNN models, using the
same shuffle method as in GLM. PAM-CNN demonstrated high performance in training and
testing, with a 0.96 AUC for both (Figure 7.7). For US-CNN (Figure 7.8), the average AUC was
0.71 in testing.

Figure 7.7: Average ROCs of PAM-CNN model. (A) training and validation results, (B) testing
results. The 95% CIs are indicated in parentheses.
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Figure 7.8: Average ROCs of US-CNN model. (A) training and validation, (B) testing results.
The 95% CIs are indicated in parentheses.

7.4 Discussion
The general architecture of the normal colon and rectal tissue consists of the mucosa (a thin layer
of epithelial cells, a layer of connective tissue, a thin layer of muscle), submucosa (mucous glands,
blood vessels, lymph vessels), muscularis propria (a thick layer of muscle), and serosa (an outer
layer of the colon). In malignancy, the individual cell types are similar, but the architecture is
distorted because cancerous cells of mucosal origin penetrate into the deeper layers of the organ.
As these cells invade, the organized structure and vascular network are lost. We have observed
uniform, layer-like vasculature with intense photoacoustic signals within normal rectal submucosa
and in the tumor beds where complete tumor destruction has occurred. In contrast, heterogeneous
and often microvascular-deficient regions have been found consistently in tumor beds with
residual cancer at treatment completion [13-14]. The return of a “normal” vascular pattern to the
tumor bed appears to signal complete tumor destruction, though this mechanism is not wellunderstood. As demonstrated, PAM-CNN captures this unique pattern and predicts pCR with a
high diagnostic accuracy. PAM-GLM uses first order statistical features extracted from PAM
histograms and these features do not contain spatial micro-features that can be leaned by deeplearning neural networks. Thus, the performance of PAM-GLM is significantly poorer than PAMCNNs.
In summary, we have shown that the performance of deep-learning based PAM-CNN models was
significantly better than that of the PAM-GLM classifier with AUC of 0.96 (95% CI: 0.95 - 0.98)
vs. 0.82 (95% CI: 0.81-0.83) using PAM Kurtosis. Both ultrasound-derived models (US-CNN and
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US-GLM) performed poorly with AUCs of 0.71 (95% CI: 0.63 – 0.78) and 0.66 (95% CI: 0.65 –
0.67), respectively. While easier to train and validate and requiring smaller data sets, GLM
diagnostic performance is inferior to CNN models.
Our study has a significant impact in rectal cancer treatment management. The PAM/US
endoscopy paired with CNNs has a great potential to improve curent standard of care imaging in
accurately predicting complete pathological response (pCR) of rectal cancer post-treatment. For
those who have achieved a pCR, unnecessary surgery can be avoided without compromising
cancer-related outcomes, and thereby lowering morbidity and health care cost.
Our study has limitations. First, the patient data is limited. With more patient data available, the
diagnostic performance of PAM-CNN models can be further improved. For example, in our
current study, 1-D ROIs from PAM and US B-scans were used as input images to CNNs.
Misclassifications can occur in ROIs’ when SNRs are low. 2-D ROIs from a small number of
sequential B-scans can be trained together to reduce the dependence of CNNs on the SNR of
individual 1-D ROIs and further improve the performance of CNNs. Second, the quality of exvivo data was not as good as in-vivo data which can be seen from slightly lower training/validation
PAM-GLM data compared with testing results of PAM-GLM. Future studies will be focused on
recruiting more patients to the study to further validate the initial results reported in this
manuscript.
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Appendix
Using highly correlated features to develop a classifier increases the chance of overfitting. To
prevent this issue, we calculated the Spearman’s correlation between each two histogram
131

features. Table S1 and S2 show the Spearman’s correlation between each pair of histogram
features of the PAM and US images, respectively. These tables are used to select an optimized
feature set before developing GLM classifiers.
Table 7.S1: Spearman’s correlation between histogram features of the PAM images
Mean

Std

Skewness

Kurtosis

Energy

Mean

1

0.79

0.72

0.42

0.79

Std

-

1

0.75

0.57

0.52

Skewness

-

-

1

0.9

0.77

Kurtosis

-

-

-

1

0.5

Energy

-

-

-

-

1

Table 7.S2: Spearman’s correlation between histogram features of the US images
Mean

Std

Skewness

Kurtosis

Energy

Mean

1

0.7

0.63

0.38

0.78

Std

-

1

0.15

0.35

0.9

Skewness

-

-

1

0.69

0.41

Kurtosis

-

-

-

1

0.52

Energy

-

-

-

-

1
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Figure 7.1S. Boxplots of histogram features (Y axes) of PAM images. Each plotted point
represents the histogram feature in one ROI. The p-value for each feature is shown on the plot.
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Figure 7.2S. Boxplots of histogram features (Y axes) of US images. Each plotted point
represents the histogram feature in one ROI. The p-value for each feature is shown on the plot
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Chapter 8: Summary and Future Work
8.1 Summary
In this dissertation, we focused on ovarian and colorectal cancer diagnosis using coregistered ultrasound
and photoacoustic tomography (PAT/US) system. We also showed the capability of our PAM/US system
in colorectal cancer diagnosis. The dissertation started by introducing some basic knowledge and statistics
about ovarian and colorectal cancer, as well as the most common tools for detecting these cancers. We then
introduced photoacoustic effect and different modalities which are based on this effect (PAT and PAM).
Next, we introduced our phantom construction procedure which can be used for pre-clinical studies of
ultrasound and photoacoustic tomography. In this gelatin-based phantom, we use different concentrations
of evaporated milk to generate desired ultrasound attenuation and optical scattering in the phantom.
Moreover, alcohol is used to achieve a speed of sound close to real tissue.
We then discussed our in-vivo study on ovarian cancer diagnosis using our PAT/US system. In that study,
we successfully classified 12 malignant and 27 ovarian ovaries using our developed GLM and SVM
classifiers. These classifiers were trained using spectral, image, and functional features extracted from our
PAT data. To extract functional features, the well-known linear unmixing method at each single pixel was
employed. This method has three problems: first, when noise and motion artifact exist in our data, the
computed functional maps are not reliable; second, the computed maps are not just a function of the
concentrations of chromophores, but also a function of PAT/US system, Grüneisen coefficient, and fluence;
third, it assumes that optical fluence is wavelength independent. We mitigated the effect of the first problem
using sliding multi-pixel method and the second problem using a two-step optimization algorithm. Solving
the third problem is very challenging and is an ongoing project.
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We then sifted our focus to colorectal cancer diagnosis. Two studies were conducted relating to this subject.
First, our PAT/US system was employed to collect data from ex-vivo colorectal cancer samples. The effects
of different treatments on colorectal lesions were quantitatively presented, and the capability of features
extracted from PAT data in distinguishing colon samples was studied (AUC of testing data set = 0.93).
Finally, in another study on colorectal cancer diagnosis, the data from PAM/US system were used to
classify rectal lesions in-vivo. We showed that a CNN classifier would significantly outperform the
performance of a GLM classifier (AUC_CNN= 0.96 vs AUC_GLM=0.82) in distinguish rectal lesions.

8.2 Future Work
8.2.1 end-to-end deep learning model to estimate functional features from PAT
data
As mentioned before, one of the limitations of our current method for evaluating functional
parameters using PAT is that we assume that optical fluence is a wavelength independent
parameter. To remove this assumption from our analysis, we are working on an end-to-end deep
learning model (U-net) to estimate optical absorption at each wavelength from the reconstructed
PA images at that wavelength. The input of this model is the reconstructed initial pressure, and the
output is absorption coefficient map. We have used digital phantoms with targets of different
shapes, sizes and locations to train the deep learning model (Figure 8.1). Monte Carlo [1] and kwave [2] toolboxes are used to estimate the optical fluence and reconstructed PA images from the
phantoms. We are also making several real phantoms (using the procedure mentioned in chapter
2) to test the performance of our classifiers. Once we assure that our model works well on our
phantom data, we apply this model on our clinical data to estimate functional feature more
accurately.
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Figure 8.1: Examples of created digital phantoms used to train our deep learning model.

8.2.2 A generalized linear model to detect invalid sO2 maps of the ovarian areas
calculated via photoacoustic tomography
To generate an sO2 map, we independently solve a linear equation at each pixel of that map. PAT
data at at least three wavelengths are required to get a robust sO2 at each pixel. These PAT data
should be higher than the noise level of the system to get a reliable estimate of sO2 at each pixel.
Some ovarian areas, such as cystic areas, have very low optical absorptions. This result in low PA
signals (less than the noise level) in most of the pixels of the map, so sO2 is not calculated for
these pixels. The remaining pixels appear as few random scattered points that although they satisfy
our condition of sO2 calculation (PAT signal>noise level), their signal levels are still not high
enough to convince us to rely on the estimated sO2 values. Detecting these maps from imaged
ovarian areas using a GLM will the aim of this study. First row of Figure 8.2 shows the maps of
some examples of accepted sO2 maps, and the second row shows examples of those that should
not be considered for further data analysis.
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Figure 8.2: Coregistered US and sO2 maps of 3 valid (a-c) and 3 invalid maps (d-f).
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